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Objectives: To provide estimates and confidence 
intervals for the performance (detection and false-
positive rates) of screening for Down’s syndrome using 
repeated measures of biochemical markers from first 
and second trimester maternal serum samples taken 
from the same woman.
Design: Stored serum on Down’s syndrome cases and 
controls was used to provide independent test data for 
the assessment of screening performance of published 
risk algorithms and for the development and testing of 
new risk assessment algorithms.
Setting: 15 screening centres across the USA, and at 
the North York General Hospital, Toronto, Canada.
Participants: 78 women with pregnancy affected 
by Down’s syndrome and 390 matched unaffected 
controls, with maternal blood samples obtained at 
11–13 and 15–18 weeks’ gestation, and women who 
received integrated prenatal screening at North York 
General Hospital at two time intervals: between 1 
December 1999 and 31 October 2003, and between 1 
October 2006 and 23 November 2007.
Interventions: Repeated measurements (first and 
second trimester) of maternal serum levels of human 
chorionic gonadotrophin (hCG), unconjugated estriol 
(uE3) and pregnancy-associated plasma protein A 
(PAPP-A) together with alpha-fetoprotein (AFP) in the 
second trimester.
Main outcome measures: Detection and false-
positive rates for screening with a threshold risk of 1 
in 200 at term, and the detection rate achieved for a 
false-positive rate of 2%.
Results: Published distributional models for Down’s 
syndrome were inconsistent with the test data. When 
these test data were classified using these models, 
screening performance deteriorated substantially 
through the addition of repeated measures. This 
contradicts the very optimistic results obtained 
from predictive modelling of performance. Simplified 
distributional assumptions showed some evidence of 
benefit from the use of repeated measures of PAPP-A 
but not for repeated measures of uE3 or hCG. Each 
of the two test data sets was used to create new 
parameter estimates against which screening test 
performance was assessed using the other data set. 
The results were equivocal but there was evidence 
suggesting improvement in screening performance 
through the use of repeated measures of PAPP-A when 
the first trimester sample was collected before 13 
weeks’ gestation. A Bayesian analysis of the combined 
data from the two test data sets showed that adding 
a second trimester repeated measurement of PAPP-A 
to the base test increased detection rates and 
reduced false-positive rates. The benefit decreased 
with increasing gestational age at the time of the first Abstract
iv
sample. There was no evidence of any benefit from 
repeated measures of hCG or uE3.
Conclusions: If realised, a reduction of 1% in false-
positive rate with no loss in detection rate would give 
important benefits in terms of health service provision 
and the large number of invasive tests avoided. The 
Bayesian analysis, which shows evidence of benefit, is 
based on strong distributional assumptions and should 
not be regarded as confirmatory. The evidence of 
potential benefit suggests the need for a prospective 
study of repeated measurements of PAPP-A with 
samples from early in the first trimester. A formal 
clinical effectiveness and cost-effectiveness analysis 
should be undertaken. This study has shown that 
the established modelling methodology for assessing 
screening performance may be optimistically biased 
and should be interpreted with caution.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Affected pregnancy  A pregnancy with a fetus 
that is affected with Down’s syndrome.
Detection rate  Proportion of affected 
pregnancies with a positive test result.
False-positive  Unaffected pregnancy that has a 
positive test result.
False-positive rate  Proportion of unaffected 
pregnancies with a positive test result.
First trimester  Prior to 14 weeks’ gestation. 
Reference maternal age distribution  The 
assumed maternal age distribution against which 
screening performance is assessed. 
Risk threshold or risk cut-off  Level of risk 
above which a test is reported as screen positive.
Second trimester  After 14 weeks’ gestation.
Screen negative  Given risk is below specified 
risk cut-off.
Screen positive  Given risk is above specified 
risk cut-off.
Weeks’ gestation  For example, week 11 
gestation means between 11 weeks + 0 days and 
11 weeks + 6 days inclusive. 
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List of abbreviations
AFP alpha-fetoprotein (denoted in 
tables and figures by a1 and a2 
for first and second trimester 
respectively)
CI confidence interval
FaSTER First and Second Trimester 
Evaluation of Risk study
hCG human chorionic gonadotrophin 
(denoted in tables and figures by 
h1 and h2 for first and second 
trimester respectively)
β-hCG free beta-human chorionic 
gonadotrophin
LL log likelihood
MoM multiple of the median
NT nuchal translucency
PAPP-A pregnancy-associated plasma 
protein A (denoted in tables and 
figures by p1 and p2 for first and 
second trimester respectively)
ROC receiver operating characteristic
STARD STAndards for the Reporting of 
Diagnostic accuracy studies
SURUSS Serum Urine and Ultrasound 
Screening Study
uE3 unconjugated estriol (denoted 
in tables and figures by u1 and 
u2 for first and second trimester 
respectively)
All abbreviations that have been used in this report are listed here unless the abbreviation is well 
known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only in 
figures/tables/appendices, in which case the abbreviation is defined in the figure legend or in the 
notes at the end of the table.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
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Objective
To provide estimates and confidence intervals (CIs) 
for the performance (detection and false-positive 
rates) of screening for Down’s syndrome using 
repeated measures of biochemical markers from 
first and second trimester maternal serum samples 
taken from the same woman.
Design
Stored serum on Down’s syndrome cases and 
controls was used to provide independent test data 
for the assessment of screening performance of 
published risk algorithms and for the development 
and testing of new risk assessment algorithms.
Setting
Two independent test data sets, including data on 
a total of 121 cases of Down’s syndrome, were used 
in the study:
•  The First and Second Trimester Evaluation 
of Risk (FaSTER) repeated measures study, 
in which samples were obtained from 15 
screening centres across the USA between 
October 1999 and December 2002.
•  The North York repeated measures study, in 
which samples were obtained from women who 
received integrated prenatal screening at the 
North York General Hospital, Toronto, Canada 
between December 1999 and November 2007.
Measurements
Repeated measurements (first and second 
trimester) of maternal serum levels of human 
chorionic gonadotrophin (hCG), unconjugated 
estriol (uE3) and pregnancy-associated plasma 
protein A (PAPP-A) together with alpha-fetoprotein 
(AFP) in the second trimester.
Outcomes
1.  Detection and false-positive rates for screening 
with a threshold risk of 1 in 200 at term.
2.  Detection rate achieved for a false-positive rate 
of 2%.
Rates were standardised to the distribution of 
maternal ages in England and Wales for the 3-year 
period from 2000 to 2002.
Results
Published distributional models for Down’s 
syndrome cases were inconsistent with the test 
data. When these test data were classified using 
these models, screening performance deteriorated 
substantially through the addition of repeated 
measures. This contradicts the very optimistic 
results obtained from predictive modelling 
of performance. Simplified distributional 
assumptions, based on the principles of linear 
discriminant analysis, improved model fit and 
showed some evidence of benefit from the use of 
repeated measures of PAPP-A but not for repeated 
measures of uE3 or hCG.
Each of the two test data sets was used to create 
new parameter estimates against which screening 
test performance was assessed using the other 
data set. The results were equivocal, but there was 
suggestive evidence of improvement in screening 
performance through the use of repeated measures 
of PAPP-A when the first trimester sample was 
collected before 13 weeks’ gestation.
A Bayesian analysis of the combined data from 
the two test data sets showed that adding a second 
trimester repeated measurement of PAPP-A to the 
base test (PAPP-A in the first trimester with AFP, 
hCG and uE3 in the second) increased detection 
rates and reduced false-positive rates. The benefit 
decreased with increasing gestational age at the 
time of the first sample. At 11 weeks’ gestation, 
the repeated measurement of PAPP-A reduced the 
Executive summaryExecutive summary
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false-positive rate by an estimated 1% (95% CI 
0.6% to 1.5%) from 3.5% to 2.5%, and increases the 
detection rate by an estimated 3% (95% CI 1% to 
6%) from 89% to 92%. There was no evidence of 
any benefit from repeated measures of hCG or uE3.
Conclusions
If realised, a reduction of 1% in false-positive rate 
with no loss in detection rate would give important 
benefits in terms of health service provision 
and the large number of invasive tests avoided. 
The Bayesian analysis, which showed evidence 
of benefit, was based on strong distributional 
assumptions and should not be regarded as 
confirmatory. The evidence of potential benefit 
suggests the need for a prospective study of 
repeated measurements of PAPP-A with samples 
from early in the first trimester. A formal clinical 
effectiveness and cost-effectiveness analysis should 
be undertaken. A secondary objective of this 
prospective study should be to investigate the 
potential value of other repeated measures markers 
including ADAM metallopeptidase domain 
12 (ADAM-12) and Inhibin-A. The additional 
complexity arising from the need to obtain serum 
samples in the first and second trimester should 
be assessed in terms of its cost-effectiveness and 
impact on screening services.
This study has shown that the established 
modelling methodology for assessing screening 
performance may be optimistically biased and 
should be interpreted with caution. Multivariate 
methods for assessment of goodness of fit and 
Bayesian methods for inference have been used in 
the analysis presented in this report and should 
be used more widely in the field of screening. 
Guidance on the use of these methods should be 
produced and software should be made available 
for their implementation.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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P
renatal screening for Down’s syndrome is 
now offered routinely in many countries 
including those in the UK (see Appendix 1 
for National Screening Committee criteria for 
appraising screening programmes). However, the 
gestational age when testing is carried out and the 
combinations of markers used vary widely.1,2 The 
use of three or four second trimester maternal 
serum measurements is common but, increasingly, 
women are being offered first trimester testing 
based on ultrasound and biochemical markers. 
In some areas, markers obtained in the first 
and second trimesters are being interpreted 
together as the integrated test.3–5 Variants such as 
sequential or contingent screening are also being 
considered.6–8 Combined testing using measures 
of the biochemical markers, pregnancy associated 
plasma protein-A (PAPP-A) and free beta-human 
chorionic gonadotrophin (β-hCG) with the 
ultrasound marker nuchal translucency (NT),9 is 
being adopted by the NHS. There is good evidence 
from a number of sources10,11 that, with appropriate 
methodology,12 this meets the current NHS 
standard of a detection rate of 75% or more for a 
false-positive rate of 3% or less. However, it fails to 
meet the standard for 2010 of a detection rate of 
90% or higher for a false-positive rate of 2% or less.
The choice of markers in screening tests has been 
influenced by the extent to which they provide 
‘independent information’ as characterised by low 
correlations between markers and the properties 
of markers when viewed individually. The 
prevailing view has been that combining markers 
with low correlations that individually have good 
discriminatory power produces screening tests with 
the best performance. Against this background, 
the integrated test3 was obtained by combining the 
best markers from the first trimester with the best 
markers from the second trimester. The Serum 
Urine and Ultrasound Screening Study (SURUSS) 
report4 concluded that the integrated test, based on 
this choice of markers, offers the most effective and 
safe current method of screening.
From the statistical perspective, however, the 
thinking behind the combination of the ‘best’ 
markers from the first trimester with the ‘best’ 
markers from the second trimester is misguided. 
This was demonstrated in the paper of Wright 
and Bradbury13 which showed, using parameter 
estimates taken from SURUSS, that highly 
correlated repeated measures of markers, some 
of which, individually, have poor discriminatory 
power, may have substantial benefits over the 
established combinations of markers used in the 
integrated test. Wald and colleagues14 have carried 
out further work on repeated measures testing, and 
have reached the same general conclusions about 
its benefit over the integrated test.
As Wright and Bradbury13 emphasise, there is a 
need for further research because of uncertainty 
in parameter estimates, departures from model 
assumptions and inherent optimistic bias in the 
established methods used to assess screening 
performance. The primary aim of the research 
reported here is to provide estimates and 
confidence intervals (CIs) for the performance 
(detection rates and false-positive rates) of 
screening tests that use repeated measures. 
This is based on two independent test data sets 
incorporating a total of 121 Down’s syndrome 
pregnancies. Results are obtained for tests 
involving repeated measures of combinations of 
PAPP-A, human chorionic gonadotrophin (hCG) 
and unconjugated estriol (uE3). In addition to the 
data available on repeated measures of PAPP-A, 
uE3 and hCG, measurements of alpha-fetoprotein 
(AFP) from the second trimester blood sample 
were available in both data sets. Data on NT and 
Inhibin-A were also available in one of the test 
data sets. The analysis presented here focuses on 
screening using tests that include combinations of 
cross-trimester repeated measures of PAPP-A, uE3 
and hCG with second trimester AFP.
This report examines the use of repeated measures 
of PAPP-A, uE3 and hCG, using the standard 
Gaussian algorithm. Estimates of screening test 
performance are presented, the goodness of 
fit of the Gaussian models for the test data sets 
is assessed and a revised screening algorithm 
suggested. In order to provide robust evidence 
of the potential benefits of repeated measures, 
each of the test data sets is used to create new 
parameter estimates against which screening test 
performance is assessed using the other test data 
Chapter 1  
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set. The two data sets are then pooled to produce a 
single screening algorithm which is assessed using 
Gaussian modelling within a Bayesian framework 
taking account of uncertainty about parameters. 
In accordance with the STAndards for the 
Reporting of Diagnostic accuracy studies (STARD) 
guidelines15 (see checklist in Appendix 2), estimates 
of screening performance are accompanied by 95% 
CIs.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
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General
Screening for Down’s syndrome involves 
the calculation of a risk based on maternal 
age, previous history of Down’s syndrome, 
measurements of biochemical markers obtained 
from maternal serum samples, and possibly 
ultrasound images. The resultant risks are 
compared with a threshold and, in cases where the 
risk is at or above the threshold, the test is deemed 
screen-positive. Otherwise, it is deemed screen-
negative. The current policy in the NHS is to use a 
risk threshold of 1 in 150 for risk assessment in the 
first trimester of pregnancy. A risk threshold of 1 
in 200 is used in the second trimester. In general, 
both false-positive and detection rates increase 
with maternal age when a screening test is applied 
with a fixed risk threshold. For unambiguous 
comparisons, it is necessary to produce estimates 
of standardised detection rates and false-positive 
rates that apply to a specific reference maternal 
age distribution. This report presents results 
for screening tests applied to the maternal age 
distribution of England and Wales for the 3 years 
from 2000 to 2002.16 Results for this reference 
distribution are presented for false-positive rates 
and detection rates obtained using a risk cut-off of 
1 in 200, and for detection rates for a fixed false-
positive rate of 2%.
Risk calculation
The calculation of risk in Down’s syndrome 
screening is an application of Bayes’ theorem17 
to combine prior information on the maternal 
age-specific risk18,19 with likelihoods obtained 
from appropriately transformed measurements 
of marker concentrations from maternal serum 
and sometimes ultrasound markers such as NT. 
Almost invariably the transformation involves two 
steps. Firstly, the measurement is expressed as a 
multiple of the median (MoM) value for unaffected 
pregnancies, standardising for gestational age 
and other variables such as maternal weight, 
smoking status and ethnicity that have effects 
on the marker concentrations.20 Secondly, a log 
transformation is used to produce a log (MoM) 
value. The likelihoods are calculated under the 
assumption that log (MoM) values follow different 
multivariate Gaussian distributions21 in unaffected 
and in Down’s syndrome pregnancies. For first 
trimester markers, it has been established that the 
mean log (MoM) in Down’s syndrome changes 
with gestational age.22 This is accommodated in 
the model by a linear regression relationship. In 
practice, the unknown parameters defining the 
multivariate Gaussian distributions are replaced 
by estimates obtained from fitting multivariate 
Gaussian models to data such as those collected 
in the SURUSS study. To deal with departures 
from the Gaussian form in the tails of the 
distribution, truncation is applied to values beyond 
a specified range. The established approach is to 
apply truncation separately to each dimension. 
We have explored an alternative multivariate 
approach, based on the Mahalanobis distance,21 
truncating values that are atypical of both Down’s 
syndrome and unaffected distributions.23 This 
avoids the production of extreme risks for atypical 
pregnancies.
It is notable that the so-called estimative 
approach24 of substituting estimates for unknown 
parameters takes no account of the uncertainty in 
the parameter estimates. A formal way of dealing 
with this uncertainty is to use Bayesian predictive 
distributions.24 However, we restrict this report to 
the estimative approach.
Assessing screening 
performance
The conventional ‘modelling’ methodology25 for 
assessing screening performance assumes that the 
class conditional distributions fitted to unaffected 
and Down’s syndrome log (MoM) values perfectly 
match the true population distributions. In 
practice, the fitted distributions will differ from the 
population distributions to some degree because 
the populations are not perfectly Gaussian and the 
fitted parameter estimates are subject to sampling 
error and biases. This means that assessment of 
screening performance under ideal modelling 
assumptions is optimistically biased. This is dealt 
with in this report as follows:
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1.  By assessing the performance of existing 
models for risk assessment on two independent 
test data sets. This avoids the optimistic 
bias associated with assuming the same 
Gaussian class conditional distributions in the 
population and in the risk calculation.
2.  Each of two test data sets is used to create new 
parameter estimates against which screening 
test performance is assessed using the other 
data set. This provides robust estimates of 
screening performance that do not rely on 
assumptions that the distributions are Gaussian 
and enables us to provide estimates of the 
screening parameters from the two test data 
sets.
3.  Distributions are fitted to the combined data 
from the two test data sets. Point and interval 
estimates are obtained under the Gaussian 
model adopting a Bayesian approach to 
inference that takes account of uncertainty 
concerning unknown parameters.26,27
Parameters
To date, three sets of parameter estimates, (I)–(III) 
below, have been published that can be used as a 
basis for screening tests with repeated measures 
of PAPP-A, hCG and uE3. All of these are based 
on secondary data published in appendices of 
the SURUSS report,4 and give very similar results 
when applied to the test data sets. This report also 
includes a fourth set of parameters obtained from 
the North York routine data and published meta-
analysis.
(I)  The original SURUSS parameter estimates4 
with corrections.28
(II)  The cross-trimester ratios parameter 
estimates obtained from SURUSS published 
by Wald and colleagues.14
(III)  The SURUSS parameter estimates 
incorporating the modifications associated 
with measurements of PAPP-A in the 
second trimester reported by Palomaki and 
colleagues23 in 2006.
(IV)  The model for the means of log (MoM) 
values taken from published meta-analyses.22 
Covariance matrices, or equivalently standard 
deviations and correlations, are estimated 
from routine data collected at North York 
General Hospital.
Parameter estimates for (I)–(IV) are given in 
Appendix 3.
In (II), measures of PAPP-A in the first trimester 
and uE3 and hCG in the second trimester were 
included as log (MoM) values. Measures of PAPP-A 
in the second trimester and uE3 and hCG in the 
first trimester were included indirectly in terms of 
log-transformed cross-trimester ratios of second 
to first trimester MoM values. The screening 
algorithm that results, apart from the effect of 
truncation, is in fact equivalent to (I).29 However, 
because of the methods of estimation used, the 
cross-trimester ratios formulation gives different 
estimates of means, standard deviations and 
correlations.30
With the exception of parameters involving second 
trimester PAPP-A, the estimates used for (III) in 
the validation study of Palomaki and colleagues23 
were taken from SURUSS. Parameter estimates 
for PAPP-A were obtained from a meta-analysis 
and from a consecutive series of 838 women 
using appropriately adjusted assays. A data set 
comprising 34 Down’s syndrome pregnancies 
and 514 unaffected pregnancies was used as 
an independent test data set. These data were 
obtained from North York and the cases are a 
subset of those comprising our test data set. New 
measurements of uE3 and hCG were made on 
first trimester samples for this Health Technology 
Assessment report.
The fourth set of parameters estimates (IV) was 
obtained from repeated measures made on routine 
samples from North York General Hospital. It 
should be emphasised that the North York test data 
were not used in the estimation of (IV). Estimation 
for (IV) was carried out using a Bayesian analysis 
implemented using WinBUGS.31
Assumptions regarding 
covariance structure
Some of the published correlation matrices are not 
positive definite14 and others are near singular. The 
practical consequences are that it is impossible to 
compute risks in cases where the correlation matrix 
is not positive definite and that the computed risks 
are implausible when the correlation matrix is near 
singular. Furthermore, assessment of screening 
performance based on models using the estimated 
covariance matrix may be grossly optimistic. The 
near singular covariance matrices arise because of 
the sparseness of data from affected pregnancies 
and the methods employed in estimation. Using 
computer simulation, we have demonstrated that 
although the standard product moment estimators DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
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are unbiased, the determinant, or generalised 
variance, of the covariance matrix is biased towards 
zero. This worsens with increasing numbers of 
markers and with novel combinations of markers. 
The approach we have taken to dealing with this 
is to impose structural assumptions relating the 
covariance matrix in Down’s syndrome to that in 
unaffected pregnancies. Screening performance is 
assessed for the following assumptions regarding 
covariance matrices:
(i)  Original covariance matrices – the covariance 
matrix for Down’s syndrome taken directly 
from the original source publications.
(ii)  Pooled covariance matrices – the population 
covariance matrices for Down’s syndrome 
and unaffected pregnancies are assumed to 
be equal. A pooled estimate of the common 
covariance matrix is used.
(iii)  Diagonally inflated covariance matrix – 
although there are some exceptions, the view 
is that the variances in Down’s syndrome 
pregnancies are likely to be larger than those 
in unaffected pregnancies. A model where the 
off-diagonal elements of the covariance matrix 
in Down’s syndrome are the same as those 
in unaffected pregnancies but the diagonal 
elements (i.e. the variances) are inflated in 
Down’s syndrome is used to capture this.
For the North York routine samples training data 
set (IV) that is assumed to contain unaffected 
pregnancies only, the analysis is restricted to 
assumption (ii) above.
Assessment of population 
screening performance
Population detection rates and false-positive 
rates for the assumed reference distribution 
were estimated as follows. Likelihood ratios were 
computed for the assumed Gaussian model. These 
were used to estimate the age-specific detection 
rates and false-positive rates. This was achieved 
by computing the proportion of likelihood ratios 
for which the risk resulting from combining 
the maternal age risk with the likelihood ratio 
exceeded the risk threshold. Population false-
positive and detection rates were obtained by 
taking the weighted average of these age-specific 
proportions with respect to the relative frequency 
distribution of maternal ages in the reference 
populations for unaffected and Down’s syndrome 
pregnancies respectively. This methodology has 
the benefit of efficiency in the sense that all of the 
available data are used at each maternal age. An 
implicit assumption involved in this calculation 
is that conditionally on karyotype (unaffected 
or Down’s syndrome), the log (MoM) values are 
independent of maternal age. This assumption is 
consistent with the available evidence. Moreover, 
the results we present are robust to moderate 
departures from this assumption. CIs were 
produced using non-parametric bootstrapping.
Assessment of goodness of fit
The fit of the various models to the independent 
test data sets was assessed using likelihood ratio-
based test statistics. These were employed as a basis 
for comparing the goodness of fit of the different 
models; not as a formal hypothesis test of goodness 
of fit.
Model fitting
The model fitting presented in this report was 
carried out using Bayesian analysis implemented 
using WinBUGS. This approach enables missing 
data to be dealt with and, through the use of 
a mixture model with contamination, robust 
estimates of parameters to be obtained without 
the need to make arbitrary or subjective decisions 
about exclusion of outliers.32 Assessment of 
screening performance under the Gaussian model 
fitted to the combined First and Second Trimester 
Evaluation of Risk (FaSTER) and North York data 
sets was carried out by sampling detection and 
false-positive rates from the posterior predictive 
distributions. Risks were calculated with the 
covariance matrices and means fixed at their 
posterior mean.
Test data
The FaSTER repeated measures data arise from a 
nested case–control study consisting of 78 Down’s 
syndrome cases and 390 matched unaffected 
controls, with maternal blood samples obtained at 
11–13 and 15–18 weeks’ gestation. Measurements 
of the integrated test markers (NT and PAPP-A 
in the first trimester and AFP, uE3, hCG and 
Inhibin-A in the second trimester) were augmented 
by measures of PAPP-A in the second trimester 
and of hCG and uE3 in the first trimester. In the 
original FaSTER study,2 samples were obtained 
from 15 screening centres across the USA between 
October 1999 and December 2002 and analysed Methods
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centrally. All centres and the central laboratory 
obtained institutional review board approval, and 
all patients provided informed consent. Outcomes 
were obtained in 97% of all pregnancies. Of 
the 117 cases of Down’s syndrome identified in 
this study, 25 were identified by first trimester 
ultrasound findings and did not have serum 
samples collected. Second trimester serum samples 
were obtained from 87 cases of Down’s syndrome. 
The case–control study is based on 78 of these 87 
cases for which there was sufficient serum to carry 
out the repeated measurements. Each of the cases 
of Down’s syndrome was matched to five controls 
for gestational ages at the times of serum sampling, 
ethnicity, maternal age and storage duration. 
Serum samples were stored at –80oC. The first 
trimester sera were thawed and tested for uE3 and 
hCG. The second trimester sera were thawed and 
tested for PAPP-A. All measurements were made 
without knowledge of whether the sample was from 
a case or control pregnancy.
The North York repeated measures data arise 
from a case–control study in which cases were 
identified from women who received integrated 
prenatal screening at North York General Hospital 
at two time intervals: (1) between 1 December 
1999 and 31 October 2003, and (2) between 1 
October 2006 and 23 November 2007. Institutional 
review board approval was obtained for the study. 
After testing, first and second trimester serum 
samples were stored at –20°C. Demographic and 
pregnancy-related information, such as maternal 
age, gestational age, maternal weight and 
pregnancy outcome, including if the pregnancy 
was affected by Down’s syndrome, was available 
from the Ontario Multiple Marker Screening 
Database. Ultrasound-based gestational age was 
between 11 and 13 completed weeks for the first 
trimester samples and 14 and 20 completed weeks 
for the second trimester samples. For each pair of 
samples obtained from a documented singleton 
Down’s syndrome pregnancy (case), five paired 
sample sets from singleton pregnancies not known 
to be affected with any chromosomal abnormality 
were selected as controls. Cases and controls were 
matched for sample date, gestational age and 
maternal age. No data on NT and Inhibin-A were 
available in the database.
First trimester PAPP-A and second trimester 
AFP, uE3 and hCG measurements in maternal 
serum (PerkinElmer Life and Analytical Sciences, 
Woodbridge, Ontario, Canada) were already 
available in the Ontario Multiple Marker Screening 
Database. The first trimester sera were thawed and 
tested for uE3 and hCG. The second trimester 
sera were thawed and tested for PAPP-A. All 
measurements were made without knowledge of 
whether the sample was from a case or control 
pregnancy. The first trimester samples were tested 
for PAPP-A after a 1:5 dilution (according to 
package insert instructions). The matching second 
trimester samples were tested in the same manner, 
but at a dilution of 1:40. Measurements were 
converted to MoM values using medians derived 
from the control samples and were adjusted for 
maternal weight using existing equations. Because 
a relatively large proportion of samples was from 
Asian women, a separate adjustment was used for 
existing markers to ensure that the median MoM 
was 1.0 in both Asian and non-Asian women.
Training data sets
Data from two separate consecutive series screening 
tests from North York were used to provide 
evidence on the covariance matrices of marker 
panels involving repeated measures of PAPP-A, 
uE3 and hCG. Research Ethics Board approval was 
obtained for these studies. The same storage and 
assay methods as for the case–control samples were 
used for these samples.
Sample 1, which includes data on repeated 
measures of uE3, hCG and PAPP-A, was obtained 
from a consecutive series of 1050 women who 
received integrated screening between January and 
April 2007. The sample was restricted to singleton 
pregnancies with no known chromosomal anomaly 
for which data on maternal weights were available. 
Pregnancies associated with insulin-dependent 
diabetic mellitus were excluded. First trimester 
PAPP-A and second trimester AFP, uE3 and hCG 
measurements of these samples were already 
available in the Ontario Multiple Marker Screening 
Database. First trimester uE3 and hCG and second 
trimester PAPP-A concentrations were measured for 
this study.
Sample 2 includes repeated measures data on 
PAPP-A from an earlier consecutive series of 838 
women. These data, reported by Palomaki and 
colleagues,23 were collected on women who received 
integrated screening during March and April 2005, 
reported as having a singleton pregnancy, with 
maternal weight and ethnicity available.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Data
Data disposition for the FaSTER and North York 
test data sets are shown in Table 1. Summary 
statistics for these data are given in Appendix 4. 
As can be seen, there are a number of pregnancies 
in the North York test data for which no second 
trimester sample data are available. These amount 
to 19% of cases of Down’s syndrome and 12% of 
the controls. Measurements on first trimester uE3 
were missing in 10 of the cases and 50 controls in 
the North York sample. These data were missing 
because there was insufficient serum available to 
complete the full panel of first trimester assays. Full 
marker information was available on 25 cases and 
123 controls.
The design used in FaSTER means that cases 
and controls were restricted to women for whom 
first and second trimester data were available. In 
the FaSTER repeated measures data, there was 
insufficient serum for assays of hCG on 9 cases 
and 125 controls giving full marker information 
on 68 cases and 224 controls. The full information 
data sets were used as test data for comparison 
of different screening strategies. Bayesian model 
fitting in WinBUGS used all available data.
Model data fit
The fit of the various fitted models, described in 
Chapter 2, was assessed using a likelihood ratio-
based test statistic (see Appendix 5). This was 
obtained from a test of the null hypothesis that the 
training data arise from the specific multivariate 
distribution with parameters taken from Appendix 
3. Under the alternative hypothesis, the data arise 
from a distribution with a different mean and 
covariance matrix. As described in Appendix 5, this 
statistic is partitioned into two additive components 
representing the lack of fit of means and of 
covariance matrices. The departure from the mean 
was represented by a linear trend with gestational 
age to allow for a gestational age-dependent error 
in mean log (MoM) values. To remove the effect 
of gross outliers, the likelihood ratio test statistic 
was computed after truncation of observations 
falling outside of the 99.9th contour of the fitted 
distribution. The results, values of –2 log likelihood 
ratio, are presented in Table 2.
For a situation involving p markers, under the 
assumption that the data arise from the particular 
model, the statistics presented in Table 2 are 
asymptotically chi-squared distributed with 
degrees of freedom: ν = 2p for the fit statistic for 
the mean and ν = p(p + 1)/2 for the fit statistic 
for the covariance matrix. Of course, in this 
analysis, the model parameters were estimated 
from training data and would be expected to 
show some departure from the true parameters, 
thus inflating this test statistic. Moreover, some 
degree of departure from a Gaussian distribution 
would be expected and this would further inflate 
the fit statistic. With p = 7 in this situation, values 
of 2p = 14 and p(p + 1)/2 = 28 provide a guide 
to interpretation, but it is the differences in 
the fit statistics across the different models and 
assumptions regarding covariance matrices that are 
important in the interpretation of Table 2.
The most notable feature of Table 2 is the relatively 
poor fit of the data from Down’s syndrome cases 
to the covariance matrices from the original 
sources (i). For parameter sets (I)–(III), the pooled 
covariance matrix, which is dominated by data 
from unaffected pregnancies, provides a better fit 
to the data in Down’s syndrome than the Down’s 
covariance matrix from the original source. It is 
also notable from Table 2 that the parameter sets 
(I)–(IV) are similar in terms of their goodness of fit 
to the test data. This is reflected in the similarity 
in screening performance when applied to the 
test data sets. In this report we present results of 
screening performance for parameter set I using 
truncation limits on MoM values from SURUSS.
Under assumptions (i) original covariance matrices 
and (ii) pooled covariance matrices, Figure 1 
shows the distribution of squared Mahalanobis 
distances from the mean for the Down’s syndrome 
pregnancies. Points with the same Mahalanobis 
distance have the same Gaussian probability 
density and fall on the same contour of the 
probability distribution, so can be considered to be 
statistically equidistant from the mean. Under the 
Gaussian model the squared Mahalanobis distances 
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TABLE 1  Gestational ages (completed weeks) for cases and controls in the FaSTER and North York (NY) test data sets and the two North 
York training data sets (NY1, NY2). For the FaSTER test data set, complete data were available on 68 cases and 224 controls. For the 
North York test data set, complete data were available on 25 cases and 123 controls
First sample
Weeks 10 11 12 13 14 Total
FaSTER Cases 0 17 36 25 0 78
Controls 0 85 180 125 0 390
NY Cases 1 4 32 5 1 43
Controls 5 20 141 30 0 196
NY1 Controls 9 114 483 232 0 838
NY2 Controls 0 420 420 210 0 1050
Second sample
Weeks 15 16 17 18 19 Total
FaSTER Cases 39 34 5 0 0 78
Controls 195 170 25 0 0 390
NY Cases 16 15 2 1 1 35
Controls 55 82 19 17 0 173
NY1 Controls 212 439 124 60 3 838
NY2 Controls 337 475 148 90 1050
Difference
Weeks 1 2 3 4 5 6 7 Total
FaSTER Cases 1 20 34 21 2 78
Controls 9 77 193 102 9 390
NY Cases 2 4 15 9 2 2 1 35
Controls 3 9 80 53 18 10 0 173
NY1 Controls 5 92 329 291 93 24 4 838
NY2 Controls 5 99 354 379 140 59 14 1050
should follow a chi-squared distribution with ν = 7 
degrees of freedom as shown by the smooth curve. 
Under assumption (i) it is clear that the training 
data are generally atypical of the assumed Gaussian 
distribution. Under assumption (ii) the degree of 
lack of fit is much less pronounced. Figure 2 shows 
the distribution of squared Mahalanobis distances 
for unaffected pregnancies. This indicates that, 
under both sets of assumptions (i) and (ii), the 
fitted covariance matrices are consistent with the 
test data.
Estimation of screening 
performance using 
independent test data
Table 3 gives standardised detection rates for the 
two repeated measures test data sets for a 2% false-
positive rate using the SURUSS screening model 
under the three different assumptions regarding 
the covariance matrix in Down’s syndrome 
pregnancies. Table 4 shows the marginal increase 
in standardised detection rates over the base test 
comprising PAPP-A in the first trimester, and 
AFP, hCG and uE3 in the second trimester. The 
2% false-positive rate was chosen as it is the 2010 
target set by the NHS National Programme (see 
Appendix 1 for National Screening Committee 
criteria for screening programmes). Table 5 presents 
standardised false-positive and detection rates 
using the term risk threshold of 1 in 200 to define 
a screen positive group. This risk threshold was 
chosen because it is the current threshold adopted 
by the NHS National Programme. Table 6 shows the 
marginal increases in standardised false-positive 
and detection rates over the base model that result 
from the inclusion of repeated measures markers. DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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FIGURE 1  Histograms of squared Mahalanobis distances of log (MoM) values of h1, p1, u1, a2, u2, h2 and p2 for Down’s syndrome 
pregnancies. Under the Gaussian model, the squared Mahalanobis distances should follow the chi-squared distribution with 7 degrees of 
freedom shown by the smooth curve. (a) North York data using SURUSS parameters with original covariance matrix; (b) North York data 
using SURUSS parameters with pooled covariance matrix; (c) FaSTER repeated measures data using SURUSS parameters with original 
covariance matrix; (d) FaSTER data using SURUSS parameters with pooled covariance matrix. Values are truncated at the 99.99th 
percentile.
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FIGURE 2  Histograms of squared Mahalanobis distances of log (MoM) values of h1, p1, u1, a2, u2, h2 and p2 for unaffected pregnancies. 
Under the Gaussian model, the squared Mahalanobis distances should follow the chi-squared distribution with 7 degrees of freedom shown 
by the smooth curve. (a) North  York data using SURUSS parameters with original covariance matrix; (b) North  York data using SURUSS 
parameters with pooled covariance matrix; (c) FaSTER repeated measures data using SURUSS parameters with original covariance matrix; 
(d) FaSTER data using SURUSS parameters with pooled covariance matrix. Values are truncated at the 99.99th percentile.Results
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TABLE 3  Standardised detection rates (%) for a 2% false-positive rate from the FaSTER and North York test data using the SURUSS 
model under assumptions (i) original covariance matrices, (ii) pooled covariance matrices and (iii) diagonally inflated covariance matrices. 
The detection and false-positive rates are for the maternal age distribution of England and Wales for the 3-year period 2000–2002. Figures 
in brackets are 95% CIs. In this and subsequent tables abbreviations p1 and p2, for example, are used to denote PAPP-A in the first and 
second trimesters respectively
Assumptions (i):  
original
Assumptions (ii):  
pooled
Assumptions (iii): 
diagonally inflated
FaSTER
p1 + a2 + u2 + h2 73 (62 to 84) 72 (61 to 83) 72 (61 to 82)
p1 + a2 + u2 + h2 + p2 70 (58 to 82) 72 (61 to 84) 70 (59 to 82)
p1 + a2 + u2 + h2 + h1 71 (59 to 83) 70 (59 to 81) 71 (60 to 81)
p1 + a2 + u2 + h2 + u1 66 (53 to 79) 72 (61 to 83) 72 (60 to 83)
p1 + a2 + u2 + h2 + p2 + u1 + h1 41 (30 to 52) 71 (59 to 82) 71 (59 to 82)
North York
p1 + a2 + u2 + h2 85 (74 to 97) 85 (70 to 99) 85 (69 to 100)
p1 + a2 + u2 + h2 + p2 86 (75 to 97) 93 (86 to 99) 91 (84 to 99)
p1 + a2 + u2 + h2 + h1 84 (73 to 96) 87 (76 to 98) 85 (69 to 100)
p1 + a2 + u2 + h2 + u1 81 (67 to 94) 84 (69 to 100) 84 (67 to 100)
p1 + a2 + u2 + h2 + p2 + u1 + h1 55 (41 to 70) 93 (86 to 99) 86 (71 to 100)
TABLE 4  Marginal increase in standardised detection rates (%) for a 2% false-positive rate from the FaSTER and North York test data 
using the SURUSS model under assumptions (i) original covariance matrices, (ii) pooled covariance matrices and (iii) diagonally inflated 
covariance matrices. The detection rates and false-positive rates are for the maternal age distribution of England and Wales for the 3-year 
period 2000–2002. Figures in brackets are 95% CIs
Assumptions (i): 
original
Assumptions (ii):  
pooled
Assumptions (iii): 
diagonally inflated
FaSTER
p1 + a2 + u2 + h2 + p2 –3 (–12 to 5) 0 (–4 to 4) –1 (–6 to 4)
p1 + a2 + u2 + h2 + h1 –3 (–7 to 2) –2 (–6 to 2) –1 (–4 to 2)
p1 + a2 + u2 + h2 + u1 –7 (–12 to –2) 0 (–2 to 2) 0 (–4 to 5)
p1 + a2 + u2 + h2 + p2 + u1 + h1 –32 (–43 to –21) –2 (–8 to 4) –1 (–7 to 5)
North York
p1 + a2 + u2 + h2 + p2 1 (–10 to 11) 8 (–4 to 20) 6 (–9 to 22)
p1 + a2 + u2 + h2 + h1 –1 (–4 to 2) 2 (–5 to 10) 0 (–1 to 2)
p1 + a2 + u2 + h2 + u1 –5 (–11 to 2) 0 (–2 to 1) –1 (–3 to 1)
p1 + a2 + u2 + h2 + p2 + u1 + h1 –30 (–46 to –14) 8 (–4 to 20) 1 (–7 to 9)
Whilst Tables 2 and 3 serve as a useful basis for 
comparing screening tests, in practice, screening 
is usually operated with a fixed risk threshold, 
so Tables 5 and 6 give a better indication of the 
practical consequence of incorporating repeated 
measures.
The most notable feature of Tables 3–6 is the 
very poor performance associated with repeated 
measures with the original Down’s syndrome 
covariance matrix. The addition of repeated 
measures of uE3, hCG and PAPP-A to the base 
test, comprising PAPP-A in the first trimester and 
AFP, uE3 and hCG in the second, reduces the 
detection rate for a fixed 2% false-positive rate 
by around 30% in both FaSTER and North York 
data sets. This is very different from the results 
obtained from modelling using the fitted Gaussian 
model from SURUSS as presented by Wright and DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 5  Standardised detection rates and false-positive rates (%) for a term risk cut-off of 1 in 200 for the FaSTER and North York test 
data using the SURUSS model under assumptions (i) original covariance matrices, (ii) pooled covariance matrices and (iii) diagonally inflated 
covariance matrices. The detection and false-positive rates are for the maternal age distribution of England and Wales for the 3-year period 
2000–2002. Figures in brackets are 95% CIs
Assumptions (i):  
original
Assumptions (ii):  
pooled
Assumptions (iii): 
diagonally inflated
FPR (%) DR (%) FPR (%) DR (%) FPR (%) DR (%)
FaSTER
p1 + a2 + u2 + h2 3.6  
(1.5 to 5.7)
79  
(72 to 86)
4.3  
(2.0 to 6.6)
80  
(73 to 86)
4.8  
(2.4 to 7.2)
80  
(74 to 87)
p1 + a2 + u2 + h2 + p2 2.4  
(0.9 to 4.0)
71  
(62 to 80)
3.1  
(0.9 to 5.3)
78  
(71 to 85)
3.4  
(1.1 to 5.7)
78  
(71 to 84)
p1 + a2 + u2 + h2 + h1 3.7  
(1.5 to 5.9)
76  
(69 to 84)
4.4  
(2.0 to 6.8)
78 
(71 to 85)
4.7  
(2.2 to 7.1)
79  
(72 to 85)
p1 + a2 + u2 + h2 + u1 4.0  
(1.7 to 6.3)
75  
(68 to 83)
4.1  
(1.8 to 6.4)
78  
(72 to 85)
4.2  
(1.9 to 6.4)
79  
(73 to 85)
p1 + a2 + u2 + h2 + p2 + 
u1 + h1
1.9  
(0.7 to 3.2)
41  
(31 to 51)
3.0  
(0.8 to 5.1)
76  
(68 to 84)
3.2  
(1.1 to 5.3)
75  
(68 to 81)
North York
p1 + a2 + u2 + h2 3.0  
(1.5 to 4.6)
89  
(78 to 100)
2.6  
(0.6 to 4.6)
90  
(80 to 99)
2.7  
(0.7 to 4.8)
91  
(82 to 100)
p1 + a2 + u2 + h2 + p2 1.4  
(0.0 to 2.8)
91  
(82 to 100)
1.2  
(0.4 to 1.9)
94  
(87 to 100)
2.1  
(0.1 to 4.0)
97  
(93 to 100)
p1 + a2 + u2 + h2 + h1 3.1  
(1.3 to 4.8)
88  
(76 to 99)
2.9  
(0.8 to 4.9)
89  
(80 to 99)
2.7  
(0.6 to 4.7)
90  
(81 to 100)
p1 + a2 + u2 + h2 + u1 3.2  
(1.4 to 5.0)
89  
(77 to 100)
2.6 ( 
0.7 to 4.6)
90  
(81 to 100)
2.5  
(0.5 to 4.5)
90  
(80 to 100)
p1 + a2 + u2 + h2 + p2 + 
u1 + h1
1.5  
(0.0 to 2.9)
63  
(46 to 80)
1.7  
(0.6 to 2.7)
95  
(87 to 100)
2.0  
(0.0 to 4.0)
96  
(89 to 100)
DR, detection rate; FPR, false-positive rate.
Bradbury13 and Wald and colleagues.14 The poor 
performance, which reflects the poor fit observed 
in Table 2 and illustrated in Figure 1, was explored 
by examining the determinants of the correlation 
matrices of the various models given in Table 7.
These determinants provide summary measures 
of the multivariate spread of the fitted distribution 
of the standardised log (MoM) values. The smaller 
determinants for Down’s syndrome pregnancies 
relative to unaffected pregnancies means that 
the fitted multivariate Gaussian distribution in 
Down’s syndrome pregnancies is concentrated 
in a relatively small region of the sample space. 
In practice, Down’s syndrome pregnancies for 
which observations fall outside this region are 
assigned low risks. Consequently, whilst modelled 
performance is very good because the population 
distributions are assumed to be the same as the 
fitted distributions, performance on test data 
is poor. Indeed, Tables 3–6 show deterioration 
in performance from the addition of repeated 
measures when using the original covariance 
matrix (i) for Down’s syndrome pregnancies. This 
is illustrated in Figure 3, which shows the modelled 
receiver operating characteristic (ROC) curves with 
the estimates and 95% CIs for the false-positive and 
detection rates obtained from the test data sets with 
a risk threshold of 1 in 200. The evidence from the 
two test data sets is that screening performance 
in practice is likely to be much worse than that 
suggested by the modelling.
Turning to the performance with pooled or 
diagonally inflated covariance matrices, the results 
from the North York and FaSTER test data sets 
are somewhat equivocal. Referring to Table 4, with 
the FaSTER test data, the addition of repeated 
measures of PAPP-A produces a marginal decrease Results
14
TABLE 6  Marginal increase in standardised detection rates and false-positive rates (%) relative to the base model p1 + a2 + u2 + h2 for a 
term risk cut-off of 1 in 200 for the FaSTER and North York test data. Risks were computed using the SURUSS model under assumptions 
(i) original covariance matrices, (ii) pooled covariance matrices and (iii) diagonally inflated covariance matrices. Detection and false-positive 
rates are for the maternal age distribution of England and Wales for the 3-year period 2000–2002. Figures in brackets are 95% CIs
Assumptions (i):  
original
Assumptions (ii):  
pooled
Assumptions (iii): 
diagonally inflated
FPR (%) DR (%) FPR (%) DR (%) FPR (%) DR (%)
FaSTER
p1 + a2 + u2 + h2 + p2 –1.2  
(–2.6 to 0.2)
–8  
(–14 to –2)
–1.2  
(–2.5 to 0.2)
–2  
(–5 to 2)
–1.4  
(–3.1 to 0.3)
–3  
(–7 to 2)
p1 + a2 + u2 + h2 + h1 0.1  
(–0.8 to 1.0)
–3  
(–5 to 0)
0.1  
(–0.7 to 1.0)
–2  
(–4 to 0)
–0.1  
(–1.0 to 0.7)
–1  
(–3 to 0)
p1 + a2 + u2 + h2 + u1 0.4  
(–0.4 to 1.2)
–4  
(–6 to –1)
–0.2  
(–0.6 to 0.1)
–1  
(–2 to 0)
–0.7  
(–1.7 to 0.4)
–1  
(–3 to 1)
p1 + a2 + u2 + h2 + p2 + 
u1 + h1
–1.7  
(–3.9 to 0.6)
–38  
(–48 to –29)
–1.3  
(–2.9 to 0.2)
–4  
(–8 to 1)
–1.6  
(–3.4 to 0.3)
–5  
(–10 to –1)
North York
p1 + a2 + u2 + h2 + p2 –1.7  
(–2.6 to –0.7)
2  
(–7 to 11)
–1.4  
(–3.6 to 0.8)
5  
(–4 to 14)
–0.7  
(–1.2 to –0.1)
6  
(–1 to 13)
p1 + a2 + u2 + h2 + h1 0.0  
(–0.7 to 0.8)
–1  
(–3 to 0)
0.3  
(–0.1 to 0.6)
0  
(–1 to 1)
–0.1  
(–0.5 to 0.3)
–1  
(–2 to 0)
p1 + a2 + u2 + h2 + u1 0.1  
(–0.9 to 1.2)
0  
(–3 to 3)
0.0  
(–0.1 to 0.2)
1  
(0 to 1)
–0.2  
(–0.6 to 0.2)
–1  
(–3 to 1)
p1 + a2 + u2 + h2 + p2 + 
u1 + h1
–1.6  
(–2.7 to –0.5)
–26  
(–42 to –10)
–0.9  
(–3.3 to 1.4)
6  
(–3 to 14)
–0.8  
(–1.5 to –0.1)
5  
(–2 to 12)
DR, detection rate; FPR, false-positive rate.
TABLE 7  Determinants of correlation matrices in unaffected and Down’s syndrome pregnancies
Training data
Assumptions regarding covariance matrix
(i) Original (ii) Pooled (iii) Diagonally inflated
I. SURUSS Controls 0.116 0.108 0.116
Cases 0.009 0.108 0.162
II. Palomaki et al. (2006)23 Controls 0.080 0.085 0.080
Cases 0.042 0.085 0.127
III. Cross-trimester ratios Controls 0.072 0.071 0.072
Cases 0.012 0.071 0.086
in estimated detection rates for the fixed 2% false-
positive rate. However, the 95% CI contains zero. 
For the North York test data the estimate shows a 
potentially important benefit for repeated measures 
of PAPP-A but, again, the CIs for the marginal 
increase in detection rates all contain zero.
The improvement in performance from assuming 
equal covariance matrices echoes results presented 
by Williams and colleagues33 in 1999, who found 
that, with smaller training samples, even the 
performance of tests with relatively few dimensions 
was improved by making the assumption of equal 
covariance matrices.
Modelling screening performance23 shows that 
any benefit of repeated measures diminishes as 
the gestational age for the first sample increases DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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FIGURE 3  Modelled receiver operating characteristics curves for screening with u1 + h1 + p1 + a2 + u2 + h2 + p2 using SURUSS 
parameters at 11 weeks’ (—), 12 weeks’(—) and 13 weeks’ (—) gestation with 95% CIs for false-positive and detection rates from the 
North York (—) and FaSTER (—) test data with a risk threshold of 1 in 200. The rectangles are the 95% CIs. The vertical and horizontal 
lines within these rectangles are the estimated false-positive rate and detection rate respectively for a risk threshold of 1 in 200.
and that the modelled benefits are negligible for 
gestational ages of 13 weeks or older. The intuitive 
explanation for this is that the benefit of repeated 
measures depends on the difference between the 
means of the repeated measures. In situations 
where the first measurement is taken late in the 
first trimester, the means across the two trimesters 
are closer together and the discriminatory power is 
reduced. Tables 8–11 show screening performance 
for the two test data sets where the gestational 
age at the time of the first sample is younger than 
13 weeks. Again, the original Down’s syndrome 
covariance matrix is associated with worsening 
screening performance with the addition of 
repeated measures. In contrast, the pooled and 
diagonally inflated covariance matrices show 
improvements, especially for repeated measures of 
PAPP-A.
Using the pooled covariance matrix for both 
FaSTER and North York data sets (see Tables 8 
and 9), the use of repeated measures of PAPP-A 
increases the estimated detection rate for a fixed 
2% false-positive rate by an estimated 5% (95% 
CI –2% to 13%) in the FaSTER data set and an 
estimated 10% (95% CI –5% to 24%) in the North 
York data set. Similarly, the estimates shown in 
Tables 10 and 11 indicate that repeated measures of 
PAPP-A have the potential to produce an important 
reduction in false-positive rates whilst maintaining 
or even increasing detection rates. However, 
because of the uncertainly reflected in the wide 
CIs associated with the relatively small samples of 
Down’s syndrome cases in the test data sets, the 
evidence cannot be considered conclusive.Results
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TABLE 8  Standardised detection rates (%) for a 2% false-positive rate from the FaSTER and North York test data with first sample 
gestations below 13 weeks. Screening using the SURUSS model under assumptions (i) original covariance matrices, (ii) pooled covariance 
matrices and (iii) diagonally inflated covariance matrices. The detection and false-positive rates are for the maternal age distribution of 
England and Wales for the 3-year period 2000–2002. Figures in brackets are 95% CIs
Assumptions (i):  
original
Assumptions (ii):  
pooled
Assumptions (iii): 
diagonally inflated
FaSTER
p1 + a2 + u2 + h2 75 (62 to 89) 75 (62 to 88) 75 (62 to 88)
p1 + a2 + u2 + h2 + p2 72 (59 to 85) 81 (69 to 92) 77 (65 to 89)
p1 + a2 + u2 + h2 + h1 74 (59 to 88) 74 (60 to 87) 74 (61 to 87)
p1 + a2 + u2 + h2 + u1 66 (50 to 82) 75 (61 to 89) 75 (60 to 90)
p1 + a2 + u2 + h2 + p2 + u1 + h1 41 (22 to 60) 79 (67 to 91) 76 (63 to 88)
North York
p1 + a2 + u2 + h2 85 (71 to 98) 83 (65 to 100) 84 (64 to 100)
p1 + a2 + u2 + h2 + p2 86 (74 to 97) 93 (87 to 99) 91 (84 to 99)
p1 + a2 + u2 + h2 + h1 84 (69 to 99) 86 (72 to 100) 84 (64 to 100)
p1 + a2 + u2 + h2 + u1 80 (67 to 94) 83 (64 to 100) 82 (62 to 100)
p1 + a2 + u2 + h2 + p2 + u1 + h1 59 (46 to 73) 93 (87 to 98) 85 (62 to 100)
TABLE 9  Marginal increase in standardised detection rates (%) for a 2% false-positive rate from the FaSTER and North York test data 
with first sample gestations below 13 weeks. Screening using the SURUSS model under assumptions (i) original covariance matrices, (ii) 
pooled covariance matrices and (iii) diagonally inflated covariance matrices. The detection and false-positive rates are for the maternal age 
distribution of England and Wales for the 3-year period 2000–2002. Figures in brackets are 95% CIs
Assumptions (i):  
original
Assumptions (ii):  
pooled
Assumptions (iii): 
diagonally inflated
FaSTER
p1 + a2 + u2 + h2 + p2 –3 (–17 to 11) 5 (–2 to 13) 2 (–7 to 11)
p1 + a2 + u2 + h2 + h1 –2 (–6 to 3) –1 (–5 to 2) –1 (–5 to 3)
p1 + a2 + u2 + h2 + u1 –9 (–15 to –3) 0 (–3 to 3) 0 (–9 to 8)
p1 + a2 + u2 + h2 + p2 + u1 + h1 –34 (–59 to –10) 4 (–4 to 12) 1 (–9 to 11)
North York
p1 + a2 + u2 + h2 + p2 1 (–17 to 19) 10 (–5 to 24) 8 (–10 to 26)
p1 + a2 + u2 + h2 + h1 –1 (–4 to 2) 3 (–6 to 11) 0 (–2 to 3)
p1 + a2 + u2 + h2 + u1 –5 (–10 to 1) –1 (–2 to 1) –1 (–4 to 1)
p1 + a2 + u2 + h2 + p2 + u1 + h1 –26 (–44 to –7) 9 (–5 to 24) 1 (–12 to 14)DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
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TABLE 10  Standardised detection and false-positive rates (%) for a term risk cut-off of 1 in 200 for the FaSTER and North York test data 
with first sample gestations below 13 weeks. Screening using the SURUSS model under assumptions (i) original covariance matrices, (ii) 
pooled covariance matrices and (iii) diagonally inflated covariance matrices. The detection and false-positive rates are for the maternal age 
distribution of England and Wales for the 3-year period 2000–2002. Figures in brackets are 95% CIs
Assumptions (i):  
original
Assumptions (ii):  
pooled
Assumptions (iii): 
diagonally inflated
FPR (%) DR (%) FPR (%) DR (%) FPR (%) DR (%)
FaSTER
p1 + a2 + u2 + h2 3.5  
(0.0 to 7.6)
81  
(71 to 91)
3.6  
(0.9 to 6.4)
81  
(72 to 91)
4.0  
(1.8 to 6.2)
81  
(72 to 91)
p1 + a2 + u2 + h2 + p2 1.3  
(0.0 to 3.8)
72  
(64 to 79)
1.8  
(0.9 to 2.7)
80  
(76 to 84)
2.0  
(1.1 to 3.0)
78  
(73 to 82)
p1 + a2 + u2 + h2 + h1 3.6  
(0.0 to 9.0)
80  
(68 to 92)
4.1  
(1.7 to 6.5)
80  
(73 to 87)
4.0  
(1.7 to 6.2)
80  
(71 to 90)
p1 + a2 + u2 + h2 + u1 4.1  
(0.0 to 9.4)
78  
(66 to 89)
3.8  
(1.6 to 6.0)
81  
(72 to 90)
3.3  
(1.0 to 5.5)
83  
(72 to 93)
p1 + a2 + u2 + h2 + p2 + 
u1 + h1
1.5  
(0.1 to 4.0)
36  
(21 to 52)
2.0  
(1.0 to 2.9)
79  
(75 to 83)
1.8  
(0.0 to 4.0)
76  
(65 to 88)
North York
p1 + a2 + u2 + h2 3.1  
(1.1 to 5.1)
88  
(77 to 99)
2.7  
(0.5 to 4.9)
89  
(79 to 99)
2.9  
(0.7 to 5.1)
91  
(81 to 100)
p1 + a2 + u2 + h2 + p2 1.5  
(0.0 to 3.1)
84  
(74 to 94)
1.1  
(0.2 to 2.0)
93  
(86 to 100)
1.4  
(0.3 to 2.5)
93  
(87 to 100)
p1 + a2 + u2 + h2 + h1 3.0  
(0.8 to 5.3)
87  
(76 to 98)
2.9  
(0.7 to 5.1)
89  
(79 to 98)
2.8  
(0.5 to 5.0)
90  
(79 to 100)
p1 + a2 + u2 + h2 + u1 3.3  
(0.7 to 5.8)
88  
(77 to 100)
2.7  
(0.6 to 4.9)
90  
(80 to 100)
2.7  
(0.4 to 5.0)
90  
(80 to 99)
p1 + a2 + u2 + h2 + p2 + 
u1 + h1
1.2  
(0.0 to 2.8)
56  
(40 to 72)
1.2  
(0.1 to 2.4)
94  
(88 to 100)
2.2  
(0.0 to 4.5)
90  
(82 to 98)
DR, detection rate; FPR, false-positive rate.Results
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TABLE 11  Marginal increase in standardised detection and false-positive rates (%) relative to the base model p1 + a2 + u2 + h2 for a 
term risk cut-off of 1 in 200 for the FaSTER and North York test data with first sample gestations below 13 weeks. Risks were computed 
using the SURUSS model under assumptions (i) original covariance matrices, (ii) pooled covariance matrices and (iii) diagonally inflated 
covariance matrices. Detection and false-positive rates are for the maternal age distribution of England and Wales for the 3-year period 
2000–2002. Figures in brackets are 95% CIs
Assumptions (i):  
original
Assumptions (ii):  
pooled
Assumptions (iii): 
diagonally inflated
FPR (%) DR (%) FPR (%) DR (%) FPR (%) DR (%)
FaSTER
p1 + a2 + u2 + h2 + p2 –2.2  
(–6.5 to 2.1)
–10  
(–21 to 1)
–1.9  
(–4.1 to 0.3)
–1  
(–10 to 7)
–2.0  
(–3.9 to –0.1)
–4  
(–12 to 4)
p1 + a2 + u2 + h2 + h1 0.1  
(–1.6 to 1.8)
–2  
(–5 to 2)
0.5  
(–0.9 to 1.8)
–1  
(–5 to 3)
–0.1  
(–0.3 to 0.2)
–1  
(–2 to 0)
p1 + a2 + u2 + h2 + u1 0.6  
(–1.4 to 2.6)
–4  
(–9 to 1)
0.1  
(–0.9 to 1.1)
–1  
(–3 to 1)
–0.8  
(–1.1 to –0.4)
1  
(–1 to 3)
p1 + a2 + u2 + h2 + p2 + 
u1 + h1
–2.0  
(–6.3 to 2.3)
–45  
(–62 to –28)
–1.7  
(–3.8 to 0.5)
–2  
(–10 to 6)
–2.2  
(–4.0 to –0.4)
–5  
(–13 to 3)
North York
p1 + a2 + u2 + h2 + p2 –1.6  
(–2.7 to –0.6)
–4  
(–16 to 8)
–1.6  
(–3.8 to 0.5)
4  
(–1 to 10)
–1.5  
(–3.7 to 0.7)
3  
(–4 to 9)
p1 + a2 + u2 + h2 + h1 –0.1  
(–0.9 to 0.8)
–2  
(–3 to 0)
0.2  
(–0.2 to 0.5)
0  
(–2 to 1)
–0.1  
(–0.5 to 0.2)
–1  
(–2 to 0)
p1 + a2 + u2 + h2 + u1 0.2  
(–1.0 to 1.4)
0  
(–4 to 4)
0.0  
(–0.1 to 0.2)
1  
(0 to 2)
–0.2  
(–0.8 to 0.4)
–1  
(–3 to 1)
p1 + a2 + u2 + h2 + p2 + 
u1 + h1
–1.9  
(–3.2 to –0.6)
–33  
(–50 to –16)
–1.5  
(–3.8 to 0.8)
5  
(–2 to 12)
–0.7  
(–1.8 to 0.4)
–1  
(–10 to 8)
DR, detection rate; FPR, false-positive rate.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
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Model fitting
The assessment of goodness of fit and screening 
performance with published parameters has 
demonstrated the limitations of the existing 
evidence for risk assessment using repeated 
measures. In particular, the correlation matrices 
for Down’s syndrome for training data sets (I)–(III) 
have unrealistically small determinants, they are 
a poor fit to the test data sets and produce poor 
screening performance. The pooled estimates 
provide a better fit and show some improvement 
in screening performance with repeated measures 
of PAPP-A, especially when the first sample is 
taken early in the first trimester. However, with the 
relatively small sample sizes, there is considerable 
uncertainty associated with these estimates. The 
purpose of this chapter is to show how new models 
were developed using the evidence available from 
the North York and FaSTER data sets. Three 
models, all based on pooled covariance matrices, 
were fitted within the Bayesian framework 
implemented using WinBUGS. One model was 
fitted to each of the two test data sets separately 
so that the other test data set could be used for 
independent cross-validation. A third model was 
fitted to the combined data set. The fitted model 
parameters are presented in Appendix 6.
Cross-validation
Tables 12–17 show the results of a cross-validation 
study using separate models fitted to each of the 
two test data sets using the other test data set for 
validation. These show similar performance to that 
achieved using the SURUSS data. These tables 
also provide estimates of screening performance 
when the same data set is used for training and 
testing. It is notable that the different results from 
a particular test data set are similar for the two 
choices of training data. The degree of optimistic 
bias encountered in these data is therefore small. 
Figure 4 shows the ROC curve produced from the 
model fitted to the combined data, together with 
estimates of screening performance from the cross-
validation using the data at 12 weeks or earlier 
(Table 16). This shows that the estimates from the 
cross-validation are broadly consistent with the 
modelled performance. Tables 16 and 17 show 
that for both FaSTER and North York samples, 
the evidence is that repeated measures of PAPP-A 
improve screening performance when the first 
trimester sample is taken at 12 weeks’ gestation or 
earlier.
Bayesian inference under 
a Gaussian model fitted to 
the combined data
Table 18 shows screening performance under 
the Gaussian model fitted to the combined test 
data sets from FaSTER and North York. Point 
estimates, together with 95% CIs, were obtained by 
sampling from the posterior predictive distribution 
of screening performance. Table 19 shows the 
marginal benefits of adding the sequence of 
repeated measures of PAPP-A (second trimester), 
hCG (first trimester) and then uE3 (first trimester) 
to the base test, comprising PAPP-A in the first 
trimester and AFP, hCG and uE3 in the second 
trimester. The evidence is that PAPP-A is the most 
promising marker for repeated measures. However, 
the benefit of this and other repeated measures 
markers diminishes with gestational age at the time 
of the first trimester sample. By 13 weeks there is 
no evidence of any benefit.
Figures 5–7 show ROC curves (bold) obtained from 
the model fitted to the combined data at 11, 12 
and 13 weeks respectively for a test using first 
trimester PAPP-A and second trimester AFP, uE3, 
hCG and PAPP-A. Estimates (posterior means) and 
95% credibility intervals for this test, with a risk 
threshold of 1 in 200, are superimposed on Figures 
5–7. These were obtained from the posterior 
distribution under the Gaussian model. For 
comparison, the ROC curves of the base test (first 
trimester PAPP-A and second trimester AFP, hCG 
and uE3) are also shown.
Chapter 4  
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TABLE 12  Standardised detection rates (%) for a screen positive rate of 2% with different combinations of FaSTER and North York 
data as test and training data. Results are presented for test data with the first sample gestations younger than 13 weeks and for the full 
range of gestations. Detection and false-positive rates are for the maternal age distribution of England and Wales for the 3-year period 
2000–2002. Figures in brackets are 95% CIs. No CIs are given for situations where the same data are used for training and testing the risk 
algorithm
Test: FaSTER Test: North York
Training: FaSTER Training: North York Training: North York Training: FaSTER
< 13 
weeks All
< 13 
weeks All
< 13 
weeks All
< 13 
weeks All
p1 + a2 + u2 + h2 76 72 75  
(62 to 88)
73  
(63 to 83)
85 87 85  
(66 to 100)
86  
(71 to 100)
p1 + a2 + u2 + h2 + p2 82 68 78  
(67 to 89)
76  
(65 to 86)
94 95 95  
(89 to 100)
95  
(89 to 100)
p1 + a2 + u2 + h2 + h1 75 68 73  
(60 to 87)
72  
(61 to 82)
85 86 84  
(69 to 98)
85  
(74 to 95)
p1 + a2 + u2 + h2 + u1 76 71 73  
(59 to 87)
73  
(63 to 83)
80 82 84  
(65 to 100)
85  
(69 to 100)
p1 + a2 + u2 + h2 + p2 
+ u1 + h1
81 65 75  
(64 to 87)
73  
(62 to 84)
93 95 95  
(89 to 100)
95  
(86 to 100)
TABLE 13  Marginal increases in standardised detection rates (%) relative to the base model p1 + a2 + u2 + h2 for a screen positive rate 
of 2% with different combinations of FaSTER and North York data as test and training data. Results are presented for test data with the 
first sample gestations younger than 13 weeks and for the full range of gestations. Detection and false-positive rates are for the maternal 
age distribution of England and Wales for the 3-year period 2000–2002. Figures in brackets are 95% CIs. No CIs are given for situations in 
which the same data are used for training and testing the risk algorithm
Test: FaSTER Test: North York
Training: FaSTER Training: North York Training: North York Training: FaSTER
< 13 
weeks All
< 13 
weeks All
< 13 
weeks All
< 13 
weeks All
p1 + a2 + u2 + h2 + p2 6 3 4  
(–3 to 11)
–3  
(–8 to 1)
9 8 13  
(–8 to 34)
9  
(–3 to 21)
p1 + a2 + u2 + h2 + h1 –1 –2 –2  
(–6 to 2)
–3  
(–6 to 0)
0 0 –5  
(–19 to 10)
–1  
(–9 to 6)
p1 + a2 + u2 + h2 + u1 0 0 –2  
(–4 to 1)
–1  
(–2 to 0)
–6 –5 –2  
(–5 to 1)
–1  
(–3 to 1)
p1 + a2 + u2 + h2 + p2 
+ u1 + h1
4 0 1  
(–7 to 8)
–7  
(–13 to 0)
7 6 12  
(–8 to 33)
9  
(–3 to 21)DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
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TABLE 14  Standardised detection rates and false-positive rates (%) for a term risk cut-off of 1 in 200 for different combinations of 
FaSTER and North York data as test and training sets. The detection and false-positive rates are for the maternal age distribution of 
England and Wales for the 3-year period 2000–2002. Figures in brackets are 95% CIs. No CIs are given for situations in which the same 
data are used for training and testing the risk algorithm
Test: FaSTER Test: North York
Training: FaSTER Training: North York Training: North York Training: FaSTER
FPR (%) DR (%) FPR (%) DR (%) FPR (%) DR (%) FPR (%) DR (%)
p1 + a2 + u2 + h2 4.1 80 3.9  
(1.7 to 6.0)
80  
(73 to 88)
3.0 90 2.6  
(0.6 to 4.7)
89  
(78 to 100)
p1 + a2 + u2 + h2 + p2 3.7 82 3.3  
(1.5 to 5.0)
78  
(71 to 85)
2.3 97 2.2  
(0.4 to 3.9)
93  
(85 to 100)
p1 + a2 + u2 + h2 + h1 4.4 79 4.1  
(1.7 to 6.5)
78  
(70 to 85)
3.0 90 2.7  
(0.7 to 4.6)
89  
(78 to 99)
p1 + a2 + u2 + h2 + u1 4.1 79 3.6  
(1.7 to 5.4)
79  
(71 to 86)
3.0 90 2.6  
(0.6 to 4.7)
89  
(78 to 100)
p1 + a2 + u2 + h2 + p2 
+ u1 + h1
4.0 82 3.1  
(1.4 to 4.8)
75  
(68 to 83)
2.5 96 2.5  
(0.7 to 4.3)
94  
(86 to 100)
DR, detection rate; FPR, false-positive rate.
TABLE 15  Marginal increases in standardised detection and false-positive rates (%) relative to the base model p1 + a2 + u2 + h2 for a 
term risk cut-off of 1 in 200 for different combinations of FaSTER and North York data as test and training data sets. The detection and 
false-positive rates are for the maternal age distribution of England and Wales for the 3-year period 2000–2002. Figures in brackets are 
95% CIs. No CIs are given for situations in which the same data are used for training and testing the risk algorithm
Test: FaSTER Test: North York
Training: FaSTER Training: North York Training: North York Training: FaSTER
FPR (%) DR (%) FPR (%) DR (%) FPR (%) DR (%) FPR (%) DR (%)
p1 + a2 + u2 + h2 + p2 –0.4 3 –0.6  
(–2.2 to 0.9)
–3  
(–8 to 3)
–0.7 7 –0.5  
(–2.5 to 1.5)
4  
(1 to 8)
p1 + a2 + u2 + h2 + h1 0.3 –1 0.2  
(–0.7 to 1.0)
–3  
(–4 to –1)
0.0 0 0.0  
(–0.2 to 0.3)
0  
(–2 to 1)
p1 + a2 + u2 + h2 + u1 0 –1 –0.3  
(–1.0 to 0.4)
–2  
(–4 to 0)
0.1 0 0.0  
(0.0 to 0.1)
0  
(0 to 0)
p1 + a2 + u2 + h2 + p2 
+ u1 + h1
–0.1 2 –0.8  
(–2.6 to 1.0)
–5  
(–11 to 1)
–0.5 7 –0.1  
(–2.3 to 2.0)
5  
(1 to 10)
DR, detection rate; FPR, false-positive rate.Development of a new screening algorithm for use in repeated measures screening
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TABLE 16  Standardised detection and false-positive rates (%) for a term risk cut-off of 1 in 200 for different combinations of FaSTER and 
North York data as test and training data sets for first sample gestations of 11 and 12 weeks or first sample gestations below 13 weeks. 
The detection and false-positive rates are for the maternal age distribution of England and Wales for the 3-year period 2000–2002. Figures 
in brackets are 95% CIs. No CIs are given for situations in which the same data are used for training and testing the risk algorithm
Test: FaSTER Test: North York
Training: FaSTER Training: North York Training: North York Training: FaSTER
FPR (%) DR (%) FPR (%) DR (%) FPR (%) DR (%) FPR (%) DR (%)
p1 + a2 + u2 + h2 3.6 82 3.2  
(0.7 to 5.7)
81  
(73 to 90)
3.2 89 2.8  
(0.9 to 4.6) 
89  
(79 to 98)
p1 + a2 + u2 + h2 + p2 2.6 85 1.7  
(0.0 to 3.7)
78  
(70 to 85)
2.4 97 2.3  
(0.7 to 3.9)
93  
(86 to 100)
p1 + a2 + u2 + h2 + h1 3.8 81 3.8  
(0.7 to 6.9)
80  
(70 to 89)
3.1 89 2.7  
(0.8 to 4.6)
88  
(79 to 97)
p1 + a2 + u2 + h2 + u1 3.6 82 3.5  
(0.9 to 6.1)
80  
(72 to 88)
3.2 90 2.8  
(0.9 to 4.6)
89  
(79 to 98)
p1 + a2 + u2 + h2 + p2 + 
u1 + h1
3.0 85 1.9  
(0.0 to 4.2)
78  
(70 to 85)
2.2 96 2.4  
(0.7 to 4.1)
94  
(88 to 100)
DR, detection rate; FPR, false-positive rate.
TABLE 17  Marginal increases in standardised detection and false-positive rates (%) relative to the base model p1 + a2 + u2 + h2 for 
a term risk cut-off of 1 in 200 for different combinations of FaSTER and North York data as test and training data sets for first sample 
gestations of 11 and 12 weeks or first sample gestations below 13 weeks. The detection and false-positive rates are for the maternal age 
distribution of England and Wales for the 3-year period 2000–2002. Figures in brackets are 95% CIs. No CIs are given for situations in 
which the same data are used for training and testing the risk algorithm
Test: FaSTER Test: North York
Training: FaSTER Training: North York Training: North York Training: FaSTER
FPR (%) DR (%) FPR (%) DR (%) FPR (%) DR (%) FPR (%) DR (%)
p1 + a2 + u2 + h2 + p2 –1.0 3 –1.5  
(–2.9 to –0.1)
–4  
(–12 to 4)
–0.7 8 –0.5  
(–2.5 to 1.6)
5  
(0 to 9)
p1 + a2 + u2 + h2 + h1 0.2 –1 0.6  
(–0.4 to 1.5)
–2  
(–4 to 1)
–0.1 0 –0.1  
(–0.2 to 0.1)
0  
(–2 to 1)
p1 + a2 + u2 + h2 + u1 0.0 –1 0.2  
(–0.3 to 0.8)
–1  
(–4 to 1)
0.0 0 0  
(–0.0 to 0.1)
0  
(0 to 0)
p1 + a2 + u2 + h2 + p2 
+ u1 + h1
–0.6 3 –1.3  
(–2.5 to –0.2)
–4  
(–11 to 3)
–0.9 7 –0.3  
(–2.4 to 1.7)
6  
(0 to 11)
DR, detection rate; FPR, false-positive rate.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
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FIGURE 4  Modelled receiver operating characteristics curves for screening with p1 + a2 + u2 + h2 + p2 at 11 weeks’ (—), 12 weeks’ (—) 
and 13 weeks’ (—) gestation. The rectangles are the 95% CIs for false-positive and detection rates from the North York (—) and FaSTER 
(—) test data using a risk threshold of 1 in 200. The vertical and horizontal lines within these rectangles are the estimated false-positive 
rate and detection rate respectively. The estimates and CIs were obtained using cross-validation. For example, the estimates and CIs for the 
North York test data were obtained from screening using the model fitted to the FaSTER test data.
TABLE 18  Screening performance of repeated measures tests relative to the base test (p1 + a2 + h2 + u2) under the Gaussian model. 
Detection and false-positive rates are for the maternal age distribution of England and Wales for the 3-year period 2000–2002 assuming a 
risk threshold of 1 in 200. Figures in brackets are 95% CIs
Week 11 Week 12 Week 13
DR (%) FPR (%) DR (%) FPR (%) DR (%) FPR (%)
(i) Base (i.e. p1 + a2 + 
h2 + u2)
88.6  
(83.8 to 93.5)
3.5  
(2.8 to 4.2)
85.7  
(81.2 to 90.2)
4.4  
(3.7 to 5.2)
82.8  
(78.2 to 87.4)
5.3  
(4.4 to 6.1)
(ii) Base + p2 91.7  
(86.9 to 96.6)
2.5  
(1.8 to 3.1)
87.6  
(83.6 to 91.6)
3.8  
(3.0 to 4.6)
83.2  
(78.4 to 88.0)
5.1  
(4.2 to 6.0)
(ii)–(i) 3.1  
(0.7 to 5.5)
–1.1  
(–1.5 to –0.6)
1.9  
(0.0 to 3.7)
–0.6  
(–1.1 to –0.2)
0.4  
(–1.0 to 1.9)
–0.1  
(–0.5 to 0.2)
(iii) Base + h1 89.6  
(85.0 to 94.1)
3.2  
(2.5 to 3.9)
85.7  
(81.2 to 90.2)
4.4  
(3.7 to 5.2
83.9  
(79.1 to 88.8)
4.9  
(4.0 to 5.7)
(iii)–(i) 0.9  
(–0.9 to 2.8)
–0.3  
(–0.6 to –0.0)
0.0  
(–0.4 to 0.4)
0.0  
(–0.2 to 0.2)
1.2  
(–1.6 to 3.9)
–0.4  
(–0.9 to 0.1)
(iv) Base + u1 88.8  
(83.9 to 93.7)
3.5  
(2.8 to 4.2)
85.7  
(81.3 to 90.2)
4.4  
(3.7 to 5.2)
82.4  
(77.9 to 87.0)
5.1  
(4.3 to 6.0)
(iv)–(i) 0.1  
(–0.8 to 1.0
–0.1  
(–0.3 to 0.2)
0.0  
(–0.4 to 0.4)
0.0  
(–0.2 to 0.2)
–0.4  
(–1.8 to 1.1)
–0.1  
(–0.4 to 0.1)
(v) Base + p2 + h1 + u1 92.6  
(87.9 to 97.3)
2.2  
(1.5 to 2.9)
87.6  
(83.6 to 91.6)
3.8  
(3.0 to 4.7)
84.0  
(79.4 to 88.6)
4.5  
(3.7 to 5.3)
(v)–(i) 4.0  
(1.0 to 6.9)
–1.3  
(–1.8 to –0.8)
1.9  
(0.1 to 3.7)
–0.6  
(–1.0 to –0.1)
1.2  
(–1.9 to 4.3)
–0.7  
(–1.3 to –0.2)
DR, detection rate; FPR, false-positive rate.Development of a new screening algorithm for use in repeated measures screening
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TABLE 19  Screening performance of repeated measures showing incremental changes from the addition of markers p2, h1 and u1. 
Detection and false-positive rates are for the maternal age distribution of England and Wales for the 3-year period 2000–2002 assuming a 
risk threshold of 1 in 200. Figures in brackets are 95% CIs
Week 11 Week 12 Week 13
DR (%) FPR (%) DR (%) FPR (%) DR (%) FPR (%)
(i) Base (i.e. 
p1 + a2 + h2 + u2)
88.6  
(83.8 to 93.5)
3.5  
(2.8 to 4.2)
85.7  
(81.2 to 90.2)
4.4  
(3.7 to 5.2)
82.8  
(78.2 to 87.4)
5.3  
(4.4 to 6.1)
(ii) Base + p2 91.7  
(86.9 to 96.6)
2.5  
(1.8 to 3.1)
87.6  
(83.6 to 91.6)
3.8  
(3.0 to 4.6)
83.2  
(78.4 to 88.0)
5.2  
(4.2 to 6.0)
(ii)–(i) 3.1  
(0.7 to 5.5)
–1.1  
(–1.5 to –0.6)
1.9  
(0.0 to 3.7)
–0.6  
(–1.1 to –0.2)
0.4  
(–1.0 to 1.9)
–0.1  
(–0.5 to 0.2)
(iii) Base + p2 + h1 92.3  
(87.6 to 97.1)
2.3  
(1.6 to 2.9)
87.7  
(83.7 to 91.6)
3.8  
(3.0 to 4.7)
84.3  
(79.4 to 89.1)
4.7  
(3.8 to 5.5)
(iii)–(ii)  0.6  
(–0.9 to 2.1)
–0.2  
(–0.2 to 0.1)
0.1  
(–0.4 to 0.5)
0.0  
(–0.3 to 0.4)
1.0  
(–1.5 to 3.6)
–0.5  
(–1.0 to 0.1)
(iv) Base + p2 + h1 + u1 92.6  
(87.9 to 97.3)
2.2  
(2.8 to 4.2)
87.6  
(83.6 to 91.6)
3.8  
(3.0 to 4.7)
84.0  
(79.4 to 89.1)
4.5  
(3.7 to 5.3)
(iv)–(iii) 0.3  
(–0.5 to 1.0)
–0.1  
(–0.4 to 0.2)
0.0  
(–0.4 to 0.4)
0.0  
(–0.4 to 0.4)
–0.3  
(–2.0 to 1.4)
–0.1  
(–0.5 to 0.2)
DR, detection rate; FPR, false-positive rate.
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FIGURE 5  Receiver operating characteristic curve for the base test p1 + a2 + h2 + u2 and for the base test + p2 (bold) when the first 
trimester sample is taken at 11 weeks’ gestation. The rectangles show 95% credibility intervals for standardised detection rates and false-
positive rates for a risk threshold of 1 in 200. These were obtained from the posterior distribution under the Gaussian model.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
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FIGURE 6  Receiver operating characteristic curve for the base test p1 + a2 + h2 + u2 and for the base test + p2 (bold) when the first 
trimester sample is taken at 12 weeks’ gestation. The rectangles show 95% credibility intervals for standardised detection rates and false-
positive rates for a risk threshold of 1 in 200. These were obtained from the posterior distribution under the Gaussian model.
80
60
40
0 4 6 2 8
False-positive rate (%)
D
e
t
e
c
t
i
o
n
 
r
a
t
e
 
(
%
)
10
100
FIGURE 7  Receiver operating characteristic curve for the base test p1 + a2 + h2 + u2 and for the base test + p2 (bold) when the first 
trimester sample is taken at 13 weeks’ gestation. The rectangles show 95% credibility intervals for standardised detection rates and false-
positive rates for a risk threshold of 1 in 200. These were obtained from the posterior distribution under the Gaussian model.Development of a new screening algorithm for use in repeated measures screening
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TABLE 20  Screening performance of repeated measures showing incremental changes from the addition of PAPP-A in the second 
trimester over the combined and quadruple test markers (first trimester NT, β-hCG, PAPP-A and second trimester AFP, uE3, hCG and 
Inhibin-A). Detection and false-positive rates are for the maternal age distribution of England and Wales for the 3-year period 2000–2002 
using a risk cut-off of 1 in 200
Week 11 Week 12 Week 13
DR (%) FPR (%) DR (%) FPR (%) DR (%) FPR (%)
(i) Combined + quadruple test  95 1.5 93 1.9 92 2.2
(ii) Combined + quadruple test + p2  97 1.1 94 1.7 92 2.2
(ii)–(i) 1 –0.4 1 –0.2 0 0
DR, detection rate; FPR, false-positive rate.
From a practical perspective, first trimester 
combined screening using NT, PAPP-A and β-hCG 
at 11–13 weeks’ gestation is the standard being 
adopted in the UK and elsewhere. The quadruple 
test comprising AFP, uE3, hCG and Inhibin-A is 
being adopted for women screened in the second 
trimester. It is therefore important to determine 
the role of repeated measures in tests incorporating 
markers from the combined test and the quadruple 
tests. Specific questions are:
•  What is the benefit of second trimester PAPP-A 
when added to the markers in the combined 
and quadruple tests?
•  What is the best subset of markers?
Using the estimates from Appendix 6 in 
conjunction with the mixture model for NT,34 the 
performance of screening using second trimester 
measurement of PAPP-A with the markers from the 
combined and quadruple tests was assessed. The 
results are presented in Table 20. With the inclusion 
of NT, the modelling produces detection rates 
well in excess of 90% for false-positive rates of less 
than 2%. The addition of PAPP-A in the second 
trimester increases detection rates marginally and 
reduces false-positive rates by 0.4% when the first 
trimester sample is taken at 11 weeks’ gestation 
and 0.2% when the first trimester sample is taken 
at 12 weeks. The addition of the second trimester 
measurement of PAPP-A is of no benefit when 
the first trimester sample is taken at 13 weeks’ 
gestation.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
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A
lthough modelling using published parameter 
estimates demonstrated substantial benefits in 
terms of detection rates and false-positive rates for 
repeated measures,13,14 we have shown that when 
applied to independent test data sets, screening 
using published parameter estimates performs very 
poorly when repeated measures are included. This 
contradiction between the model predictions and 
the results from real data can be explained by the 
unrealistically small determinants of the published 
correlation matrices for Down’s syndrome 
pregnancies. These small determinants mean 
that the fitted distribution for Down’s syndrome 
pregnancies is concentrated in a relatively 
small region. Under the modelling assumption, 
where the population reflects the model and 
measurements on Down’s syndrome pregnancies 
arise from this highly concentrated distribution, 
screening performance is exceptionally good. 
However, in reality, data on Down’s syndrome 
pregnancies exhibit more variability than the fitted 
model and so risks computed from the model are 
unrealistically low in many cases.
Evidence has been presented that, when risks 
are computed from models based on structured 
covariance matrices, screening performance can 
be improved using repeated measures of PAPP-A. 
In these models, the covariance matrix for Down’s 
syndrome pregnancies is constrained so that it 
is linked to the covariance matrix for unaffected 
pregnancies. The simplest constraint is to make the 
covariance matrix in Down’s syndrome pregnancies 
the same as that in unaffected pregnancies. This 
assumption leads to the use of linear discriminant 
analysis,21 as previously suggested by Williams and 
colleagues.33 This assumption has benefits in terms 
of simplicity and ensures that the likelihood ratio is 
a monotonic function of the MoM values.
The evidence comes from three analyses of 
the marginal benefit of adding a repeated 
measurement of PAPP-A in the second trimester to 
a base test comprising PAPP-A in the first trimester 
and AFP, uE3 and hCG in the second.
Firstly, using bootstrapping to provide CIs, we 
have used the FaSTER and North York data sets 
to carry out independent validation studies of 
the performance of screening using published 
parameters. The strength of this approach is 
its robustness. Although the risks are computed 
under the assumptions of a Gaussian model, 
no parametric assumptions are involved in 
the assessment of screening performance. The 
weakness of this approach is the lack of precision as 
reflected by relatively wide CIs.
Secondly, using a Bayesian approach, separate 
models have been fitted to the FaSTER and North 
York data sets, and a cross-validation study, using 
the same non-parametric bootstrapping approach 
to obtain CIs, has been applied.
Thirdly, adopting a Bayesian approach, we 
have obtained credibility intervals for screening 
performance under the Gaussian model fitted 
to the combined test data sets from FaSTER and 
North York.
The Bayesian analysis shows evidence of substantial 
benefits from the use of repeated measures of 
PAPP-A in situations where the first trimester 
sample is taken at 11 weeks’ gestation. These 
model-based results are generally consistent with 
the cross-validation studies but show greater 
precision. At 11 weeks, the repeated measurement 
of PAPP-A reduced the false-positive rate by an 
estimated 1% (95% CI 0.6% to 1.5%) from 3.5% 
to 2.5% and increased the detection rate by an 
estimated 3% (95% CI 1% to 6%) from 89% to 92%. 
There is little evidence of benefit from repeated 
measures of hCG or uE3. The evidence also 
suggests that any benefit from repeated measures 
of PAPP-A diminishes with increases in gestation 
of the first trimester sample, and by 13 weeks’ 
gestation the repeated measurement of PAPP-A has 
little to add to screening performance.
The evidence of a reduction of around 1% in 
false-positive rate, with no loss in detection rate, 
has important benefits in terms of health service 
provision and the large number of invasive tests 
avoided. For example, in a screened population 
of 100,000, an expected 1000 invasive tests and 
10 fetal losses would be avoided. The results from 
this study therefore provide evidence to support 
a prospective study of repeated measurements of 
Chapter 5  
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PAPP-A. They also suggest that any such study 
should focus on samples taken early (between 8 
and 12 weeks) during the first trimester. A formal 
clinical effectiveness and cost-effectiveness analysis 
should be undertaken. A secondary objective of any 
such prospective study should be to investigate the 
potential value of other repeated measures markers 
including ADAM-12 and Inhibin-A. The additional 
complexity arising from the need to obtain serum 
samples in the first and second trimester is an 
important practical consideration. The use of 
contingent screening6,7 with intermediate risks 
can be used to reduce the need for the second 
sample in around 80% of women with very little 
impact on screening performance. There is a 
need to assess effectiveness of repeated measures 
screening policies, including those that make use 
of contingent strategies, from the perspectives of 
women, service provision and health economics.
First trimester combined screening using NT, 
PAPP-A and β-hCG at 11–13 weeks’ gestation is the 
standard being adopted in the UK and elsewhere. 
The quadruple test comprising AFP, uE3, hCG and 
Inhibin-A is being adopted for women screened in 
the second trimester. The results presented in this 
report suggest that, if the first trimester sample 
is taken at 11 weeks, adding repeated measures 
of PAPP-A to the combined test and quadruple 
test markers reduces false-positive rates by an 
estimated 0.4% from 1.5% to 1.1% with no loss in 
detection rate. It is envisaged that any prospective 
studies of repeated measures of PAPP-A would 
involve its inclusion in a panel of second trimester 
markers from the quadruple test following the 
combined test, either as an integrated test or a 
contingent screening test.6,7 This would enable the 
benefits of adding second trimester PAPP-A to the 
combined test and quadruple test markers to be 
assessed prospectively and the different marker 
combinations to be compared.
The results presented in this report are based on 
the use of multivariate methods for assessment of 
goodness of fit and bootstrapping and Bayesian 
methods for inference. The possibility of using 
a predictive approach to account for uncertainty 
in parameters in assessment of risk has also 
been discussed. Further methodological work 
of this kind would be of great benefit in terms 
of improvements in service provision and policy 
making.
The development and evaluation of risk assessment 
and screening tests for Down’s syndrome and other 
maternal and fetal conditions requires samples 
from large numbers of affected pregnancies. 
Where centres are able to collect blood at two 
different stages of pregnancy and separate and 
store serum samples under controlled conditions 
until the outcome of pregnancy is known, it would 
be of considerable value if an aliquot of these 
samples along with suitable matched control sera 
could be donated to a central serum bank for 
long-term storage. This would provide a valuable 
resource facilitating further research to improve 
prenatal care across a range of maternal and fetal 
conditions.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
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Appendix 1  
National Screening Committee criteria for 
appraising the viability, effectiveness and 
appropriateness of a screening programme
I
deally all the following criteria should be met 
before screening for a condition is initiated:
The condition
1.  The condition should be an important health 
problem.
2.  The epidemiology and natural history of the 
condition, including development from latent 
to declared disease, should be adequately 
understood and there should be a detectable 
risk factor, disease marker, latent period or 
early symptomatic stage.
3.  All the cost-effective primary prevention 
interventions should have been implemented 
as far as practicable.
4.  If the carriers of a mutation are identified as 
a result of screening, the natural history of 
people with this status should be understood, 
including the psychological implications.
The test
1.  There should be a simple, safe, precise and 
validated screening test.
2.  The distribution of test values in the target 
population should be known, and a suitable 
cut-off level defined and agreed.
3.  The test should be acceptable to the 
population.
4.  There should be an agreed policy on the 
further diagnostic investigation of individuals 
with a positive test result and on the choices 
available to those individuals.
5.  If the test is for mutations, the criteria used 
to select the subset of mutations to be covered 
by screening, if all possible mutations are not 
being tested, should be clearly set out.
The treatment
1.  There should be an effective treatment or 
intervention for patients identified through 
early detection, with evidence of early 
treatment leading to better outcomes than late 
treatment.
2.  There should be agreed evidence-based 
policies covering which individuals should 
be offered treatment and the appropriate 
treatment to be offered.
3.  Clinical management of the condition and 
patient outcomes should be optimised in all 
health-care providers prior to participation in a 
screening programme.
The screening programme
1.  There should be evidence from high quality 
randomised controlled trials that the screening 
programme is effective in reducing mortality or 
morbidity.
2.  Where screening is aimed solely at providing 
information to allow the person being screened 
to make an ‘informed choice’ (e.g. Down’s 
syndrome, cystic fibrosis carrier screening), 
there must be evidence from high quality trials 
that the test accurately measures risk. The 
information that is provided about the test 
and its outcome must be of value and readily 
understood by the individual being screened.
3.  There should be evidence that the complete 
screening programme (test, diagnostic 
procedures, treatment/intervention) is clinically, 
socially and ethically acceptable to health 
professionals and the public.
4.  The benefit from the screening programme 
should outweigh the physical and psychological 
harm (caused by the test, diagnostic procedures 
and treatment).
5.  The opportunity cost of the screening 
programme (including testing, diagnosis and 
treatment, administration, training and quality 
assurance) should be economically balanced 
in relation to expenditure on medical care as a 
whole (i.e. value for money).
6.  There should be a plan for managing and 
monitoring the screening programme, and an 
agreed set of quality assurance standards.Appendix 1
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7.  Adequate staffing and facilities for testing, 
diagnosis, treatment and programme 
management should be available prior to the 
commencement of the screening programme.
8.  All other options for managing the condition 
should have been considered (e.g. improving 
treatment, providing other services) to ensure 
that no more cost-effective intervention 
could be introduced or current interventions 
increased within the resources available.
9.  Evidence-based information, explaining 
the consequences of testing, investigation 
and treatment, should be made available to 
potential participants to assist them in making 
an informed choice.
10. Public pressure for widening the eligibility 
criteria for reducing the screening interval, 
and for increasing the sensitivity of the testing 
process, should be anticipated. Decisions 
about these parameters should be scientifically 
justifiable to the public.
11. If screening is for a mutation, the programme 
should be acceptable to people identified as 
carriers and to other family members.
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Appendix 2  
STARD checklist for reporting of studies of 
diagnostic accuracy (version January 2009)
Section and topic Item On pages 
TITLE/ABSTRACT/
KEYWORDS
1 Identify the article as a study of diagnostic accuracy (recommend MeSH heading 
‘sensitivity and specificity’)
i, iii–iv
INTRODUCTION 2 State the research questions or study aims, such as estimating diagnostic 
accuracy or comparing accuracy between tests or across participant groups
1–2
METHODS 3–6
Participants 3 The study population: The inclusion and exclusion criteria, setting and locations 
where data were collected
4 Participant recruitment: Was recruitment based on presenting symptoms, results 
from previous tests, or the fact that the participants had received the index 
tests or the reference standard?
5 Participant sampling: Was the study population a consecutive series of 
participants defined by the selection criteria in items 3 and 4? If not, specify how 
participants were further selected
6 Data collection: Was data collection planned before the index test and reference 
standard were performed (prospective study) or after (retrospective study)?
Test methods 7 The reference standard and its rationale
8 Technical specifications of material and methods involved including how and 
when measurements were taken, and/or cited references for index tests and 
reference standard
9 Definition of and rationale for the units, cut-offs and/or categories of the results 
of the index tests and the reference standard
10 The number, training and expertise of the persons executing and reading the 
index tests and the reference standard
11 Whether or not the readers of the index tests and reference standard were 
blind (masked) to the results of the other test and describe any other clinical 
information available to the readers
Statistical methods 12 Methods for calculating or comparing measures of diagnostic accuracy, and the 
statistical methods used to quantify uncertainty (e.g. 95% confidence intervals)
13 Methods for calculating test reproducibility, if done
RESULTS 7–18
Participants 14 When study was performed, including beginning and end dates of recruitment
15 Clinical and demographic characteristics of the study population (at least 
information on age, gender, spectrum of presenting symptoms)
16 The number of participants satisfying the criteria for inclusion who did or 
did not undergo the index tests and/or the reference standard; describe 
why participants failed to undergo either test (a flow diagram is strongly 
recommended)
Test results 17 Time interval between the index tests and the reference standard, and any 
treatment administered in between
18 Distribution of severity of disease (define criteria) in those with the target 
condition; other diagnoses in participants without the target condition
19 A cross-tabulation of the results of the index tests (including indeterminate and 
missing results) by the results of the reference standard; for continuous results, 
the distribution of the test results by the results of the reference standard
20 Any adverse events from performing the index tests or the reference standardAppendix 2
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Section and topic Item On pages 
Estimates 21 Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% 
confidence intervals)
22 How indeterminate results, missing data and outliers of the index tests were 
handled
23 Estimates of variability of diagnostic accuracy between subgroups of participants, 
readers or centres, if done
24 Estimates of test reproducibility, if done.
DISCUSSION 25 Discuss the clinical applicability of the study findings 27–28
MeSH, medical subject headings.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
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TABLE 21  Mean log MoM values in Down’s syndrome pregnancies by week
Parameter
Mean log MoM in Down’s syndrome pregnancies
SURUSS CT ratios
Week  
10
Week 
11
Week 
12
Week 
13
Week 
10
Week 
11
Week 
12
Week 
13
First trimester
NT 0.3820 0.3367 0.2913 0.2460 0.3820 0.3367 0.2913 0.2460
AFP –0.0655 –0.0655 –0.0655 –0.0655 –0.2380 –0.1839 –0.1264 –0.0703
uE3 –0.0044 –0.0605 –0.1024 –0.1427 –0.0182 –0.0525 –0.0843 –0.1187
hCG –0.0177 0.1038 0.1875 0.2742 0.0565 0.0970 0.1357 0.1751
β-hCG 0.2095 0.2878 0.3404 0.3944 0.2850 0.3076 0.3280 0.3494
Inhibin-A –0.0269 0.1303 0.2380 0.3384 0.1131 0.1453 0.1770 0.2113
PAPP-A –0.4685 –0.3768 –0.3010 –0.2366 –0.4685 –0.3768 –0.3010 –0.2366
Second trimester
AFP –0.1308 –0.1308 –0.1308 –0.1308 –0.1308 –0.1308 –0.1308 –0.1308
uE3 –0.1549 –0.1549 –0.1549 –0.1549 –0.1549 –0.1549 –0.1549 –0.1549
hCG 0.3118 0.3118 0.3118 0.3118 0.3118 0.3118 0.3118 0.3118
β-hCG 0.4249 0.4249 0.4249 0.4249 0.4249 0.4249 0.4249 0.4249
Inhibin-A 0.3384 0.3384 0.3384 0.3384 0.3384 0.3384 0.3384 0.3384
PAPP-A 0.0453 0.0453 0.0453 0.0453 –0.0740 –0.0344 –0.0087 0.0039
CT, cross-trimester.
Appendix 3  
Parameter estimates from 
training data sets I–IVAppendix 3
38
TABLE 22  Standard deviations of log MoM values in Down’s syndrome and unaffected pregnancies. The SURUSS estimates were 
obtained from Wald et al. (2003)4,5 incorporating changes from Wald et al. (2004)35 and Wald et al. (2006).28 Palomaki et al. (2006)23 use 
a standard deviation of 0.243 for second-trimester PAPP-A in unaffected pregnancies. All other standard deviations are as published in the 
SURUSS report
Parameter Week
Standard deviations of log MoM 
in unaffected pregnancies
Standard deviations of log 
MoM in Down’s syndrome 
pregnancies
Estimated 
common SD 
from the North 
York training 
data SURUSS CT ratios SURUSS CT ratios
First trimester
NT 10 0.1732 0.1732 0.2313 0.2313
11 0.1439 0.1439
12–13 0.1329 0.1329
AFP 0.1818 0.1788 0.1672 0.1832
uE3 0.1204 0.1183 0.1720 0.1708 0.1190
hCG 0.1950 0.1999 0.2069 0.1817 0.2007
β-hCG 0.2651 0.2605 0.2569 0.2417
Inhibin-A 0.2191 0.2057 0.2343 0.2112
PAPP-A 0.2495 0.2495 0.2802 0.2802 0.2421
Second trimester
AFP 0.1399 0.1399 0.1398 0.1398 0.1355
uE3 0.1142 0.1142 0.1238 0.1238 0.1066
hCG 0.2276 0.2276 0.2395 0.2395 0.2186
β-hCG 0.2577 0.2577 0.2965 0.2965
Inhibin-A 0.2078 0.2078 0.2679 0.2679
PAPP-A 0.2549 0.2451 0.2203 0.2227 0.2408
CT, cross-trimester; SD, standard deviation.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Appendix 4  
Summary statistics for sample data
TABLE 28  Distribution of ethnic origin in FaSTER and North York samples. Figures in brackets are percentages
FaSTER Caucasian Asian Oriental American 
Indian
Hispanic Black Other
Cases 49 (63) 3 (4) 0 (0) 0 (0) 17 (22) 4 (5) 5 (6)
Controls 263 (67) 14 (4) 2 (1) 1 (0) 65 (17) 20 (5) 25 (6)
North York Caucasian Asian Other Unknown
Cases 19 (44) 19 (44) 3 (7) 2 (5)
Controls 95 (44) 95 (44) 15 (7) 10 (5)
North York routine Caucasian Asian Other Unknown Aboriginal Black
NY1 570 (54) 340 (32) 46 (4) 17 (2) 3 (0) 74 (7)
NY2 485 (58) 258 (31) 20 (2) 19 (2) 0 (0) 56 (7)
TABLE 29  Distribution of maternal ages (years) in FaSTER and North York data sets
n Minimum Maximum Mean Standard deviation
FaSTER
Cases 78 19 46.7 37.3 5.1
Controls 390 16.9 45.2 32.5 5.53
North York
Cases 43 23.05 46.06 36.4 4.9
Controls 215 18.51 49.11 31.8 4.9
North York routine
NY1 1050 16 45 31.2 4.8
NY2 838 16 45 31.3 4.5
TABLE 30  Distribution of maternal weights (lb) in FaSTER and North York data sets
n Minimum Maximum Mean Standard deviation
FaSTER
Cases 78 98 259 147 30.7
Controls 390 95 308 143 27.5
North York
Cases 37a 104 208 144 25.4
Controls 215 100 235 141 22.4
North York routine
NY1 1050 89 321 147 34.1
NY2 838 92 395 145 34.5
a  Six cases with missing maternal weights.DOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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A
s a numerical measure of lack of fit between 
the published parameters and the data, we 
consider a generalised likelihood ratio test of the 
null hypothesis:
H0: δ = 0 and Σ = Σ0
where δ denotes the difference between the mean 
log multiple of the median (MoM) from the data 
and the published mean. In general, the mean 
log MoM is zero in unaffected pregnancies and 
is dependent on gestational age in pregnancies 
affected by Down’s syndrome. Σ denotes the 
covariance matrix of the vector x of log MoM 
values, and Σ0 denotes the covariance matrix 
obtained from the published standard deviations 
and correlations.
The aim is to quantify departures from the model 
in terms of the way the covariance differs from Σ0 
and δ may differ from zero. We assume departures 
from zero according to a simple linear regression 
model on gestational age.
The generalised likelihood ratio test statistic, based 
on the likelihood l0 under the published model and 
the likelihood l1 under the model fitted to the log 
MoM values x1, x2, … xn is given by:
−





 = +
− ∑ 2
0
1
0 0
1 log ln(| |)
l
l
n x x
i i
i
Σ Σ
T
− − − −
− ∑ n S x S x
i i i i
T
i
ln(| |) ( ˆ ) ( ˆ ) δ δ
1
where ˆ δ
i  is the estimated value of δ from a linear 
regression on gestational age and S is the sample 
covariance matrix. A total of 2p parameters are 
involved in the regression model and p(p + 1)/2 are 
involved in the covariance matrix.
Under H0, this likelihood ratio test statistic is 
approximately χ2 distributed with p(p + 5)/2 degrees 
of freedom. This can be partitioned into two 
additive components:
ˆ ˆ δ δ
i i
T
i
Σ
0
1 − ∑
and
n x x
i i
i
i i
T ln(| |) ( ˆ ) ( ˆ ) Σ Σ
0 0
1 + − − ∑
− δ δ
− − − − ∑
− n S x S x
i i
i
i i
T ln(| |) ( ˆ ) ( ˆ )
0
1 δ δ
The first component represents the deviation of δi 
from 0, while the second measures the deviation 
of Σ from Σ0. Under H0, these components are 
approximately independently χ2 distributed with 2p 
and p(p + 1)/2 degrees of freedom respectively.  We 
use these test statistics not for formal hypothesis 
tests but as measures of the lack of fit between 
the published parameters and the data. If the 
published parameters explain the data well, then 
the statistics above should be close to the respective 
degrees of freedom. Large values of these tests 
statistics are indicative of lack of fit.
Appendix 5  
Likelihood ratio test statisticsDOI: 10.3310/hta14330  Health Technology Assessment 2010; Vol. 14: No. 33
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Appendix 6  
Models fitted to FaSTER and 
North York test data
TABLE 31  Fitted regression models for mean log MoM values in Down’s syndrome pregnancies
Marker
FaSTER North York Combined
α β α β α β
First trimester
AFP
uE3 –0.08836 –0.002313 –0.066 –0.008899 –0.07718 –0.005606
hCG 0.1463 0.01065 0.2441 0.01556 0.1952 0.013105
β-hCG
Inhibin-A
PAPP-A –0.3144 0.01016 –0.3431 0.01927 –0.32875 0.014715
Second trimester
AFP –0.1337 0 –0.09654 0 –0.11512 0
uE3 –0.1845 0 –0.1325 0 –0.1585 0
hCG 0.2980 0 0.4011 0 0.34955 0
β-hCG 0 0 0
Inhibin-A 0 0 0
PAPP-A –0.08962 0 –0.008819 0 –0.04922 0
Fitted model: mean log MoM = α + β(GA – 87). GA denotes gestational age in days.
TABLE 32  Standard deviations of log MoM values – the standard deviations are assumed to be the same in Down’s syndrome and 
unaffected pregnancies
Marker FaSTER North York Combined
First trimester
AFP
uE3 0.1347 0.1212 0.1306
hCG 0.1804 0.1861 0.1835
β-hCG
Inhibin-A
PAPP-A 0.2399 0.2518 0.2436
Second trimester
AFP 0.1397 0.1342 0.1381
uE3 0.1350 0.1125 0.1286
hCG 0.2203 0.2172 0.2201
β-hCG
Inhibin-A
PAPP-A 0.2141 0.2257 0.2181Appendix 6
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Feedback
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your views about this report.
The Correspondence Page on the HTA website 
(www.hta.ac.uk) is a convenient way to publish  
your comments. If you prefer, you can send your comments  
to the address below, telling us whether you would like  
us to transfer them to the website.
We look forward to hearing from you.